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ABSTRACT 
 
Preeclampsia (PE) is a major cause of maternal and fetal morbidity and mortality. 
The maternal symptoms are diverse and the neonates are often born premature and 
growth-restricted. Today the survival of premature infants has increased, but the 
neonatal complications including morbidity and long-term developmental deficits are 
still common. 
 
The etiology and pathophysiological mechanisms in PE are still not known, but it 
seems as if a central part of the pathogenesis is associated with an unsuccessful 
implantation of the placenta into the uterus. The only cure is to deliver the mother, 
which is often a difficult decision in regard to prematurity of the fetus, when the 
disease has begun early in pregnancy.  
 
In our first and second studies, we examined the placental pathology in relation to the 
maternal symptoms and severity of disease. The first study showed that there was a 
correlation between the severity of symptoms and the placental pathology. Further, 
the pathological picture was similar in mild and severe PE, but differed in relation to 
controls. To summarize, mild PE seems to be part of the PE spectrum, and not a 
normal physiological development of pregnancy, in contrast to what has previously 
been claimed.     
 
The second study showed that placental pathology differed in severe PE with and 
without HELLP syndrome (hemolysis, elevated liver enzymes and low platelets), 
which is a disease regarded as a PE subtype, although the clinical picture is different 
from classical PE. This indicates that other mechanisms might be involved in the 
HELLP syndrome. 
 
In the third and fourth studies, we examined the placental pathology in relation to 
perinatal, neonatal and childhood outcome. In the third study, we investigated the 
relation between placental pathology and perinatal and neonatal outcome in a cohort 
of PE patients and found that placental pathology was associated with adverse 
outcome. In the fourth study, in which we studied infants born extremely premature, 
we also found correlations between placental pathology and perinatal and neonatal 
outcome. 
 
In the fourth study, we also explored possible relations between placental pathology 
and neurologic and developmental outcome of the child at the age of 2.5 years. We 
found a significant association between placental infarction and cerebral palsy (CP), 
and tendencies between several pathological findings and developmental outcome.  
 
Overall, we have shown that the underlying pathologies in mild and severe PE 
probably are similar, whereas HELLP syndrome might have a different etiology. In 
addition, we have found associations between placental pathology and outcome of the 
offspring.  
  
LIST OF PUBLICATIONS 
 
I.  Marie-Therese Vinnars, Josefine Nasiell, Sam Ghazi, Magnus Westgren, 
Nikos Papadogiannakis.  
The severity of clinical manifestations in preeclampsia correlates with the 
amount of placental infarction.  
ACTA Obstet Gynecol Scand. 2011;90:19-25. 
 
II.  Marie-Therese Vinnars, Liliane CD Wijnaendts, Magnus Westgren, 
Annemieke C Bolte, Nikos Papadogiannakis, Josefine Nasiell.  
Severe preeclampsia with and without HELLP differ with regard to placental 
pathology.  
Hypertension. 2008;51:1295-9.  
 
III.  Marie-Therese Vinnars, Josefine Nasiell, Gerd Holmström, Mikael Norman, 
Magnus Westgren, Nikos Papadogiannakis. 
Placental pathology and neonatal outcome in preeclampsia: a large cohort 
study. 
Submitted. 
 
IV.  Marie-Therese Vinnars, Nikos Papadogiannakis, Josefine Nasiell, Gerd 
Holmström, Brigitte Vollmer, Magnus Westgren. 
Placental pathology in relation to neonatal and development outcome at 2.5 
years of age in an extremely premature population: a prospective cohort study. 
Submitted. 
 
  
CONTENTS 
 
List of abbreviations ............................................................................................. 7 
1 Introduction ................................................................................................... 8 
2 Background ................................................................................................... 9 
2.1 The beginning of life ........................................................................... 9 
2.2 The placenta ........................................................................................ 9 
2.2.1 Development ........................................................................... 9 
2.2.2 Gross anatomy ...................................................................... 10 
2.2.3 Placental pathology ............................................................... 11 
2.3 Preeclampsia (PE) ............................................................................. 17 
2.3.1 Definition .............................................................................. 17 
2.3.2 Epidemiology ........................................................................ 17 
2.3.3 Pathophysiology ................................................................... 18 
2.3.4 Doppler ultrasound ............................................................... 21 
2.3.5 Treatment for PE................................................................... 21 
2.3.6 Consequences of PE for the infant ....................................... 22 
2.4 Prematurity ........................................................................................ 23 
2.4.1 Definition .............................................................................. 23 
2.4.2 Etiology ................................................................................. 23 
2.4.1 Epidemiology ........................................................................ 23 
2.4.2 Consequences of prematurity for the infant ......................... 23 
2.5 The offspring ..................................................................................... 24 
2.5.1 The normal scenario ............................................................. 24 
2.5.2 Adverse outcome .................................................................. 25 
3 Aims of the thesis ....................................................................................... 29 
4 Material and methods ................................................................................. 30 
4.1 Placental examination ....................................................................... 30 
4.1.1 Macroscopic examination..................................................... 30 
4.1.2 Microscopic examination ..................................................... 31 
4.2 Study designs and populations ......................................................... 32 
4.2.1 Study I ................................................................................... 32 
4.2.2 Study II .................................................................................. 33 
4.2.3 Study III ................................................................................ 34 
4.2.4 Study IV ................................................................................ 35 
4.3 Statistics............................................................................................. 36 
4.3.1 Study I ................................................................................... 36 
4.3.2 Study II .................................................................................. 36 
4.3.3 Study III ................................................................................ 36 
4.3.4 Study IV ................................................................................ 36 
4.4 Ethics permission .............................................................................. 37 
5 Results ......................................................................................................... 38 
5.1 Study I ............................................................................................... 38 
5.1.1 Placental pathology ............................................................... 38 
5.1.2 Sub groups ............................................................................ 39 
  
5.2 Study II .............................................................................................. 40 
5.2.1 Placental pathology .............................................................. 40 
5.2.2 Placental weight .................................................................... 40 
5.2.3 Birth weight .......................................................................... 41 
5.3 Study III ............................................................................................ 41 
5.3.1 Placental pathology .............................................................. 41 
5.3.2 Umbilical artery blood flow ................................................. 42 
5.3.3 Perinatal and neonatal outcome ........................................... 42 
5.3.4 Placental pathology and outcome ........................................ 43 
5.4 Study IV ............................................................................................ 45 
5.4.1 Placental pathology .............................................................. 45 
5.4.2 Outcome of the offspring ..................................................... 46 
5.4.3 Placental pathology and outcome of the offspring .............. 46 
6 Discussion ................................................................................................... 49 
6.1 Methodological considerations ......................................................... 49 
6.1.1 Study designs ........................................................................ 49 
6.1.2 Type I and type II errors ....................................................... 50 
6.1.3 Biases .................................................................................... 50 
6.2 Findings and interpretations ............................................................. 53 
7 Conclusions ................................................................................................. 58 
8 Future perspectives ..................................................................................... 59 
9 Sammanfattning på svenska ....................................................................... 60 
9.1 Bakgrund ........................................................................................... 60 
9.2 Frågeställningar................................................................................. 61 
9.3 Studie I .............................................................................................. 61 
9.4 Studie II ............................................................................................. 61 
9.5 Studie III ............................................................................................ 62 
9.6 Studie IV ........................................................................................... 62 
9.7 Slutsatser ........................................................................................... 63 
10 Acknowledgements .................................................................................... 64 
11 References ................................................................................................... 66 
 
  
LIST OF ABBREVIATIONS 
 
AEDF Absent end diastolic flow 
AGA Appropriate for gestational age 
ALAT  Alanine aminotransferase 
ANCOVA Analysis of covariance 
ASAT Aspartate aminotransferase 
BMI Body mass index 
BPD Bronchopulmonary dysplasia 
CI Confidence interval 
CP Cerebral palsy 
DNA Deoxyribonucleic acid 
DM Diabetes mellitus 
EXPRESS Extremely preterm infants in Sweden study 
HELLP Hemolysis, elevated liver enzymes and low platelets 
HLA Human lymphocyte antigen 
IUFD Intrauterine fetal death 
IVF In vitro fertilization 
IVH Intraventricular hemorrhage 
MFR Medical Birth Registry 
NEC Necrotizing enterocolitis 
NK Natural killer 
OR Odds ratio 
PE Preeclampsia 
PI Pulsatile index 
PNQ Perinatal Quality Registry 
PPROM Preterm premature rupture of the membranes 
PVL Periventricular leucomalacia 
RA Rheumatoid arthritis 
REDF Reversed end diastolic flow 
RNA Ribonucleic acid 
ROP Retinopathy of prematurity 
SD Standard deviation 
sFlt-1 Soluble vascular endothelial growth factor receptor-1 
SGA Small for gestational age 
  
 
 8 
1 INTRODUCTION 
 
Papyrus documents from around 2000 B.C. that have been found to describe 
gynecological disorders and contraceptives at that time are possibly also the first 
documentation of eclampsia, described as a suffering from the teeth and inability to 
open the mouth and if affecting the pubic region as far as the clavicles and the buttocks, 
indicating an incurable disease.
1, 2
   
 
Eclampsia is a state of convulsions with a mortality rate as high as 14% in some 
countries, while the risk to succumb is much lower in other parts of the world.
3
 
Eclampsia progresses from preeclampsia (PE), a pregnancy-specific hypertensive 
disorder affecting 2-7% of pregnant women worldwide.
3, 4
 Eclampsia and PE are not 
only affecting the mother, but are also associated with high morbidity and mortality in 
the infants.
3, 4
    
 
In the year 2000, the United Nations set up 10 Millennium Development Goals, two of 
which were to lower maternal and child mortality.
5
 Maternal mortality varies greatly 
depending on geographical area. Women living in middle- and high-income countries 
have a pregnancy-related mortality risk of one in 4 000 – 20 000, whereas the 
corresponding risk in some low-income countries is reported as high as up to one in 
15.
6, 7
 In African and Asian countries, the most common causes of maternal deaths 
related to pregnancy are hemorrhage, infections and hypertensive disorders.
8
    
 
In Sweden, and in many other countries, the maternal and reproductive care is well 
developed and regular antenatal controls by midwives contribute to an earlier 
identification of women suffering from PE, thus making it possible to intervene when 
needed. Curative treatment is however not available, but if necessary, labor can be 
induced. Conservative management consists of administration of antihypertensive 
drugs and magnesium sulfate, and/or expectancy.
9
 In spite of the extensive prenatal 
care, hypertensive disorders are the greatest single cause of maternal deaths in high-
income countries, accounting for one in six of maternal deaths.
8
 
 
Depending on factors such as gestational age and severity of disease, up to 67% of PE 
infants are reported to be born prematurely.
4
 In high-income countries, the survival 
rates of very preterm birth infants have increased, but neonatal morbidities and delayed 
development are common problems with decreasing gestational age.
10, 11
     
 
Today, 4000 years after the ancient Egypt, women and infants still succumb and suffer 
as a consequence of eclampsia and PE and the etiology of the disease is still unknown.
4
 
It is essential to elucidate the pathophysiological mechanisms in PE, as part of an 
attempt to find strategies in preventing the development and progression of the disease 
and in treating and possibly also curing the women and infants affected.  
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2 BACKGROUND 
 
2.1 THE BEGINNING OF LIFE 
The embryonic development begins when an oocyte and spermatocyte fuse and form a 
zygote. The zygote travels towards the uterine cavity and meanwhile, cell division 
occurs. By day four, the zygote has become a 32-cell mass, looking like a mulberry and 
called morula (latin word for mulberry). The morula reaches the uterine cavity by day 
six and is now called a blastocyst, which will implant into the uterine wall.
12
  
 
In a non-pregnant woman, the spiral arteries in the uterine wall have each month grown 
longer and finally collapse, giving rise to a menstruation. When an embryo implants, 
the arteries are transformed so that they can satisfy the infant’s need for nutrients and 
oxygen.
12
 
 
2.2 THE PLACENTA 
2.2.1 Development 
The blastocyst consists of trophoblast cells, which will form the fetal side of the 
placenta, and embryoblast cells, which will form the fetus. As the blastocyst adheres to 
the uterine wall, some of the trophoblasts start to proliferate, lose their cell membranes 
and fuse. These, so called syncytiotrophoblasts, expand and finally surround the entire 
embryo. Within the syncytiotrophoblasts, trophoblastic lacunae form, see figure 1.
12
 
 
As a response to the implantation of the blastocyst, the endometrial stroma becomes 
highly vascularized and thickened. The endometrium has developed into a decidua, 
which will form the maternal side of the placenta. The capillaries of the maternal spiral 
arteries become maternal sinusoids, which anastomose with the trophoblastic lacunae 
and become filled with maternal blood, see figure 1. This is the beginning of the 
uteroplacental circulation.
12
  
               
                     
 
 
 
 
 
 
 
 
 
 
 
                            
 Figure 1. An implanted blastocyst. Reprinted with permission from John Wiley and Sons, Inc.  
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The trophoblasts that did not become syncytiotrophoblasts are called cytotrophoblasts. 
Covered by syncytiotrophoblasts they are forming several extensions, called villi, 
which grow into the blood filled lacunae. Later on, embryonic cells will form fetal 
blood vessels that will be found within those villi. The lacunae have now fused together 
and become one space, into which the villous trees expand. Hence, the room is called 
the intervillous space. The layer of cytotrophoblasts and syncytiotrophoblasts between 
the fetal blood vessels in the villi and the maternal blood in the intervillous space make 
up the placental bed barrier, and is called the syncytiotrophoblastic membrane. The 
development of the villous structure will continue during the entire pregnancy. Villi at 
different gestational weeks can be seen in figure 3A and C.
12, 13
 
 
In a normal pregnancy, the spiral arteries become transformed. The vasoreactive 
endothelial and smooth muscle cells of the artery walls are exchanged with trophoblast 
cells that do not respond to vasoconstrictors and hence, those arteries are constantly 
dilated and unconditionally filling the intervillous space with maternal blood. Oxygen 
and nutrients thereafter diffuse through the placental bed barrier and are further 
transported within the fetal veins which are located in the villi. Merging together they 
form one umbilical vein continuing towards the infant. In the other direction, two 
umbilical arteries transport (poorly oxygenated) fetal blood from the infant through the 
umbilical cord towards the placenta.
12-14
 
 
2.2.2 Gross anatomy 
The placenta is made out of both maternal and fetal tissue, as is described above. It can 
be divided into the placental disk, the membranes (amnion and chorion) and the 
umbilical cord, see figure 2. The placental disk consists of the decidua, where the 
maternal blood vessels (spiral arteries) are; and the chorionic plate, which is on the fetal 
side of the placenta. The space between the maternal decidua and the fetal chorionic 
plate is the blood filled intervillous space, in which fetal chorionic villi are located. The 
umbilical cord is normally inserted on the chorionic plate. The fetal side of the placenta 
is covered by an amniotic and a chorionic membrane which also surround the entire 
fetus.
13
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Placental structure. Reprinted with permission from John Wiley and Sons, Inc. 
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2.2.3 Placental pathology 
The focus of this thesis is on placental pathology that is related to PE, prematurity and 
adverse fetal outcome. In general, much of the pathology discussed in this thesis is 
related to perfusion defects.  
 
2.2.3.1 Pathology often seen in PE 
2.2.3.1.1 Decidual arteriopathy 
The invasion of trophoblasts into the spiral arteries does not occur sufficiently in all 
pregnancies and as a consequence the spiral arteries continue to constrict in response to 
vasoconstrictors.
14-18
 The corresponding histopathological findings are hypertrophy of 
the smooth muscle of the artery wall and hyperplasia of the endothelium. Later on, 
fibrinoid necrosis of the wall, luminal thrombosis and atherosis of the artery walls are 
present.
19
 In acute atherosis foamy macrophages are localized within the spiral artery 
wall.
13
 Some of the signs in decidual arteriopathy can be seen in figure 4A and B.  
 
Absent transformation of the spiral arteries is primarily associated with PE and fetal 
growth restriction
14, 19
, but some studies have more recently also showed associations 
with spontaneous abortions in second trimester and preterm labor.
20, 21
 Some years ago, 
Redline et al
22
 showed an increased risk for cerebral palsy (CP) in cases with acute 
atherosis. 
 
Acute atherosis resembles arteriosclerosis and is also related to later cardiovascular 
disease of both mother and infant. PE and cardiovascular disease have many common 
risk factors and pregnancy could be regarded as a stress test of the mother’s 
susceptibility for cardiovascular disease.
23
 
 
2.2.3.1.2 Placental infarctions 
The villi, and in continuation the infant, are dependent on the maternal vessels’ supply 
with oxygen. As a consequence of occlusion of maternal arteries the adjacent villi 
become infarcted. Infarctions can be seen grossly, especially if they are of older age, 
becoming pale, and if they are extensive. Histologically they represent typical ischemic 
necrosis of placental parenchyma, i.e. chorionic villi. Initially, the intervillous space 
within the ischemic area is reduced, and villi tend to aggregate and are congested with 
dilated capillaries. Further on, pyknosis and karyorrhexis can be seen. After a longer 
time the villous structure looks like a shadow of the former villi, sometimes referred to 
as ghost villi, see figure 5B.
13, 24
  
 
Placental villous infarctions of greater extent are more common in hypoxia, fetal 
growth restriction, intrauterine fetal death (IUFD) and PE.
13
 Ischemic changes in the 
villi have also been associated with periventricular leucomalacia (PVL)
25, 26
 and 
macroscopic placental infarctions have been related to CP in the infant.
27, 28
 A study by 
van Vliet et al
29
, comparing infants affected by chorioamnionitis and placental 
underperfusion, among other signs including infarctions, found a lower developmental 
score at 2 years of age in the underperfusion-group.
29
 Another similar study
30
 did not 
find any association, but had a smaller material, shorter duration of follow-up and did 
not adjust for confounding factors.    
 12 
 
Infarctions involving <5% of the tissue can be found in 25% of normal term placentas. 
Infarctions of small extent and especially if located in the periphery are not associated 
with adverse outcome.
13, 19
  
 
2.2.3.1.3 Intervillous thrombosis 
The untransformed spiral arteries seen especially in PE and fetal growth restriction are 
proposed to be causing a disruptive turbulence of the blood flow within the intervillous 
space.
31, 32
 Here, so called intervillous thromboses can be seen macroscopically, but can 
be mistaken for infarctions without histological confirmation.
13, 33
 Microscopically, 
they are characterized by fibrin lamellae mixed with fetal and maternal erythrocytes. 
See figure 6A. Later on, the blood cells degenerate and the laminations become more 
compact. Especially in PE and fetal growth restriction, the intervillous thromboses can 
be found.
13
  
 
Hutchinson et al
34
 performed a study on a placenta perfusion model, in which they 
altered the blood flow to the placenta and examined the impact on the villi. They found 
that an alternation in the hemodynamics, as in PE, had a destructive effect on the villi 
and resulted in a release of factors associated with endothelial disruption, hence 
suggesting a link between changes in blood flow to the placenta and maternal 
symptoms.   
 
2.2.3.1.4 Accelerated villous maturation 
Reduced blood supply to the placenta can lead to an acceleration of the placental villi. 
The villi become smaller, involve less stroma and the so-called syncytiovascular 
membrane, separating the fetal and maternal blood, becomes thinner. This morphology 
is very similar to the appearance of a term placental villi. See figure 3A-C. The 
phenomenon is more common in preterm birth, PE and fetal growth restriction, but can 
also be seen in placentas from smoking mothers.
13, 24
  
 
2.2.3.1.5 Abnormal placental weight 
The placental weight is often affected by a reduced uteroplacental blood flow. A low 
placental weight in relation to its gestational age is related to both a low birth weight 
and presence of placental infarctions that can also be associated with an adverse blood 
flow in the placenta.
13
 A small placenta in relation to its gestational age is common in 
hypertension, PE, diabetic vasculopathy and fetal growth restriction. Small placentas 
can also be observed in association with chromosomal abnormalities.
13, 24
  
 
However, more recently, also a higher frequency of large placentas in relation to 
gestational age has been reported in a population of term PE.
35
 A large placenta is more 
common in maternal diabetes mellitus (DM), fetal hydrops, hemoglobinopathy, Rh 
incompatibility, acute and chronic infection, maternal anemia and overgrowth 
syndromes. The placenta can also be heavier as a result of a retroplacental hematoma or 
maternal fluid administration during cesarean section.
13
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2.2.3.1.6 Abruptio placentae 
Abruption of the placenta is a premature separation of the implanted placenta from the 
uterine wall due to the rupture of maternal arteries. The cause is unknown, but risk 
factors such as PE, hypertension, smoking, cocaine use, chorioamnionitis and 
premature rupture of the membranes have been identified.
13
 
 
Placental abruption could cause abdominal pain and is a leading cause of vaginal 
bleeding in the second half of pregnancy, but can also occur without any bleeding 
symptoms. The abruption can be partial or total and depending on the extent, the 
consequences differ greatly. A total abruption can cause fetal death, whereas a partial 
abruption could become chronic and result in no obvious symptoms or sequelae.
36
 
 
There is often a discrepancy between the obstetric and histopathologic diagnosis of 
abruption. The clinically diagnosed abruption is more often acute and is only verified 
by the pathologist in 30% of the cases. On the contrary, a pathological finding of a 
retroplacental hematoma, indicating an abruption, is only coexisting with a clinical 
diagnosis in 35% of the cases. Whereas an acute abruption could be histopathologically 
undetected, chronic abruptions not only give rise to organized blood clots and craters of 
the placental tissue, but also to additional histological findings such as hemosiderin 
deposits or signs of reduced placental perfusion.
13, 36
 See figure 7A. 
 
2.2.3.2 Some other common pathology features 
2.2.3.2.1 Fetal thrombosis 
Fetal thromboses are arterial or venous and are localized either in the vessels of the 
umbilical cord, the chorionic plate or the villous tree. A careful macroscopical 
examination may identify the thrombosis, which in the acute phase can be seen 
histologically as a laminated thrombosis attached to the endothelial surface. If chronic, 
the thrombosis often has undergone a transformation making the vessel wall organized 
and thickened. See figure 6B. The etiology of fetal vascular thrombosis is probably 
multifactorial.
13, 19, 37, 38
 
 
Fetal thrombosis can result in an embolic event both in fetal and placental direction, 
depending on the type of vessel. In the presence of an arterial thrombosis, the event 
could occur in the villi, resulting in atrophy of the villi and, if extensive, result in 
growth restriction or fetal death. On the other hand, in case of a venous thrombosis, the 
embolic event could happen in the infant and have an impact on the fetal brain, viscera 
or upper extremity.
13, 24
 
 
Fetal thromboses have been related to IUFD, fetal growth restriction, neonatal 
encephalopathy and delayed development.
26, 39-44
 Some studies
45, 46
 have not seen any 
relation between fetal thrombotic pathology and neonatal brain injury, but they have 
been smaller and not taken confounding factors into account. However, although 
studying a limited number of patients, Elbers et al
47
 found a high incidence of fetal 
thrombosis in a group of patients with neonatal stroke.    
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2.2.3.2.2 Chorioamnionitis 
Acute chorioamnionitis is the most frequent placental finding in infants born before 
gestational age 32 with a decreasing prevalence with advancing gestational age. It is an 
inflammatory response localized to the membranes and the chorionic plate. Most often 
microbes ascending from the urogenital tract are responsible for the inflammatory 
response. The symptoms of acute chorioamnionitis are maternal fever, leukocytosis, 
prolonged rupture of the membranes, uterine tenderness, foul smelling amniotic fluid 
and fetal tachycardia. A so called silent chorioamnionitis can be diagnosed 
histologically when none of these symptoms is present.
13, 48, 49
 
 
Histologically, maternal neutrophils are found in the membranes, the umbilical cord, 
the chorionic plate and/or the subchorionic space. Fetal neutrophils may be observed in 
the fetal vessels of the chorionic plate or umbilical cord. Macroscopically, the 
membranes may be thickened and have a yellowish color because of the inflammatory 
exsudate.
13, 48, 49
 See figure 7B.   
 
Acute chorioamnionitis is related to placental abruption, preterm birth and adverse 
perinatal outcome.
36, 37, 48
 It has been further associated to pulmonary disorders, sepsis 
and cerebral complications in the neonate, but studies have shown discrepant results.
22, 
26, 43-45, 50-64
 A likely underlying mechanism could be formation of thrombosis in the 
fetal vessels that are damaged from the inflammatory cells. Those could hypothetically 
embolize via the umbilical cord to the fetal lung and brain.
37
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A. Normal appearance of the villi in gestational week 29. B. Accelerated villous maturation in 
gestational week 29. C. Normal appearance of villi at term.  
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Figure 4A and B. Decidual arteriopathy is seen in the maternal blood vessels as dilated lumen, fibrinoid 
necrosis of the vessel wall and presence of foamy macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5A and B. Placental infarction is seen in right picture, normal villi from the same placenta in the 
left. This infarction is of older age, composed of so called ghost villi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6A. Intervillous thrombosis can be seen to the left, normal term placenta to the right. The 
thrombus is of older age, as fibrin lamination is present, and contains both maternal and fetal 
erythrocytes. 6B. Dilated chorionic plate vessels with fetal thromboses. The vessel in the upper part of the 
picture shows so-called endothelial cushion with intimal mural fibrin deposition. The vessel in the lower 
part shows older, laminated fibrin thrombus with occlusion of the lumen. 
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Figure 7A. Placental abruption with older retroplacental clot, creating crater formation (left) and 
adjacent infarction (upper left). B. Chorioamnionitis with neutrophils in the subchorionic space as well as 
in chorion and amnion layers.   
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2.3 PREECLAMPSIA (PE) 
2.3.1 Definition 
PE is a pregnancy specific syndrome mainly based on presence of hypertension and 
proteinuria. According to current criteria, PE is diagnosed in the presence of a systolic 
blood pressure of 140 mmHg or higher or a diastolic of 90 mmHg or higher on two 
occasions at least six hours apart, and proteinuria, defined as an excretion of at least 0.3 
gram protein during 24 hours.
65, 66
 The symptoms can occur at any time after 20 weeks 
gestation, but early debut is usually more serious, and suggestions have been made to 
divide PE into an early- and late-onset syndrome.
67
 Placental pathology is reported to 
be more frequent and severe in early gestational age.
68
  
 
2.3.1.1 Severe PE 
PE is clinically divided into a mild and a severe form. Severe PE is diagnosed in the 
presence of even higher blood pressure, proteinuria, fetal growth restriction or maternal 
complications. Presence of symptoms included in table 1 indicates a severe form of the 
syndrome.
65
 If not treated, PE can progress to eclampsia, defined as the development of 
convulsions or coma in PE patients.
3
  
 
Table 1. Indication of severe PE
65
   
Systolic blood pressure ≥ 160 mmHg 
Diastolic blood pressure ≥ 110 mmHg 
Proteinuria ≥ 5 g/24 hour 
Oliguria <500 mL/24 hour 
Cerebral or visual disturbances 
Pulmonary edema or cyanosis 
Epigastric or right upper-quadrant pain 
Impaired liver function 
Trombocytopenia 
Fetal growth restriction 
 
2.3.1.2 HELLP syndrome 
Another severe complication of PE is HELLP syndrome (acronym for hemolysis, 
elevated liver enzymes and low platelets). In addition to hypertension and proteinuria, 
typical symptoms in HELLP syndrome are malaise, upper quadrant tenderness, nausea 
and vomiting. Diagnosis of HELLP is based on laboratory findings and subjective 
symptoms such as epigastric pain. The presence of hemolysis is best defined as low 
haptoglobin levels, elevated liver enzymes are often defined as an elevation of alanine 
aminotransferas (ALAT) and aspartate aminotransferas (ASAT) above 2-3 standard 
deviations (SD) above the mean and thrombocytopenia defined as platelets ≤ 100.000 
/µl. Hypertension and proteinuria is absent in 10-15% of women with HELLP 
syndrome, suggesting a possible heterogeneity within this disease entity.
4, 69, 70
 
 
2.3.2 Epidemiology 
PE affects approximately 2-7% of pregnant women worldwide and is associated with 
both maternal and fetal mortality and morbidity. Although outcome is better in the 
developed world, PE accounts for 15-20% of maternal mortality.
4
 Along with 
 18 
hemorrhage and infection, hypertension is the major maternal complication in 
pregnancy.
71
 
72
 In three quarter of the cases, the syndrome starts near term, but it can 
also begin as early as in gestational week 20. Preterm delivery is reported in 15-67% 
and fetal growth restriction in 10-25% of PE pregnancies.
4
   
 
2.3.3 Pathophysiology 
The etiology of PE is still unknown, although it is established that the presence of a 
placenta is necessary in the development of PE. It is also generally accepted that a 
normal pregnancy is achieved through a successful implantation of the placenta into the 
uterine wall and that the placental implantation in PE seems to be incomplete.
21
  
 
2.3.3.1 The disease of theories 
As the speculations have been many, PE has been described as the disease of theories. 
One of the leading theories at the moment is that there is a maternal immunological 
response to the fetal immune system, resulting in abnormal transformation of the spiral 
arteries, giving rise to some of the pathology described above. See figure 8A-B. The 
absence of transformed spiral arteries leads to a high-resistance blood flow to the 
placenta. The turbulence of the blood flow and hypoxia in the placenta then give rise to 
a destruction of placental tissue and release of factors, such as soluble vascular 
endothelial growth factor receptor-1 (sFlt-1), syncytiotrophoblast membrane 
microparticles, fetal ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), which 
might injure maternal endothelium and be responsible for the maternal symptoms.
4, 21, 
73-76
 In addition, a breakage of the placental bed barrier has also been shown in PE 
patients.
77
 
 
 
 
  
 
 
 
 
 
 
  
  
Figure 8A: Normal trophoblast invasion into the spiral arteries, resulting in a low-resistance blood flow. 
B: Incomplete transformation of the spiral arteries, seen in PE, resulting in a high-resistance blood flow. 
Reprinted with permission from Eunice Kennedy Shriver NICHD, National Institutes of Health, U.S. 
                              
2.3.3.2 Immunological considerations 
The reason for the failed implantation in PE is unknown, but it has been speculated 
whether PE is a type of rejection of the fetus, similar to the rejection of a transplanted 
organ. Incomplete placental implantation has recently also been associated with 
spontaneous abortions.
20, 21
 Some researchers have also speculated whether PE might 
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be an autoimmune disorder.
78
 Inevitably, the fetal cells carry genetic material both from 
the mother (that is recognizable) and from the father (that is foreign).
79
  
 
After mating, an inflammatory response can be seen in the female genital tract, giving 
an opportunity for the maternal immune system to process the paternal antigens. This 
could direct the maternal immunological response towards a tolerant T helper 2-
response
4
, which has been found to be related to a successful pregnancy.
80
 On the other 
hand, a T helper 1-response, which is less tolerant, is more common in PE, but also in 
miscarriages.
80
 However, T- and B-cells are not common populations in the placenta 
and the role of NK (natural killer) cells has also been discussed.
81, 82
 Also, it has been 
speculated whether NK cells could mediate the change in T helper type.
83
   
 
Several risk factors (see table 2) have been identified that would support the idea of an 
adaptation and development of a tolerance towards the paternal antigens. Robillard et 
al
84, 85
 found that the time of cohabitation before conception was inversely related to the 
risk of pregnancy induced hypertension. Also, others have shown an increased risk for 
PE after short cohabitation and after use of barrier contraception
86
 as well as a 
decreased risk for PE if the coupled had practiced oral sex before the pregnancy.
87
 The 
risk for PE is also higher in the first pregnancy than in the proceeding and both 
previous abortions and healthy pregnancies are protective against PE.
88-91
 However, 
with change of partner, the protective effect of a previous pregnancy or abortion is 
lost.
88, 92
 
 
Studies on donated ova and sperm cells also support this theory. A study by Salha et 
al
93
 showed higher frequencies of PE in patients who had received sperm (18%), ovum 
(16%) or embryo (25%) donation than in a control group (0-3.7%). Also, they found 
more PE in women who had undergone in vitro fertilization (IVF) if the sperm cells 
came from a donor (18%) than if they came from their partner (0%). Wang et al
79
 
hypothesized that couples in need of surgical obtainment of sperm cells might have an 
increased risk of PE as the female had not been exposed to the sperm cells prior to 
conception. They found that those couples had a threefold risk for PE compared with 
couples where IVF was performed with ejaculated sperm cells.    
 
2.3.3.3 Maternal PE 
Why an abnormal placental implantation results in PE in some women and in fetal 
growth restriction, spontaneous abortion or preterm prelabor rupture of the membranes 
in others is not clear.
21
 One can speculate whether those obstetrical issues are different 
sides of the same coin. However, it has been proposed that defective implantation is 
linked to the maternal symptoms in PE by a metabolic syndrome in the mother, which 
is not present in fetal growth restriction without PE.
94
  
 
Maternal obesity
89, 95-99
, DM
4, 95
, insulin resistance
100
, hypertension and renal disease
95, 
98, 101, 102
, thrombophilia
103
 and rheumatoid arthritis (RA)
104
 have been identified as risk 
factors for PE (see table 2). With the exception of smoking, which decreases the risk 
for PE
89, 95, 98
, cardiovascular disease and PE share many risk factors.
23
 Also, PE 
increases the risk for later cardiovascular disease.
105-107
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The profile of maternal risk factors outlined above has led some authors to propose a 
division of PE into a maternal and a placental type of the disease. In the maternal form, 
a mother with many cardiovascular risk factors could develop PE as a response to a 
normal pregnancy with corresponding degree of inflammation. Conversely, in the 
placental form, a mother without any risk factors could develop PE as a response to a 
malfunctioning placenta with a higher degree of inflammation than in a normal 
pregnancy.
74
 
 
Table 2. Risk factors for PE   
First pregnancy
4, 91
 
Limited sperm exposure
84, 86, 87
  
Donation of ovum, sperm or embryo
79
 
Obesity
89, 95-99
 
DM
89, 95
 
Insulin resistance
100
 
Hypertension and renal disease
95, 98, 101, 102
 
RA
104
 
Non-smoking
89, 95, 98
 
Multifetal gestation
108, 109
 
Heredity
110-113
 
Previous PE
114
 
Thrombophilia
103
 
 
Many substances have been found to be released from the placenta into the maternal 
circulation.
4
 The amount of those might also influence the presence of maternal 
symptoms, which could explain why women with multiple gestation
108, 109
 have a 
higher risk of PE. 
 
2.3.3.4 Genetic factors 
Previous studies have also shown that genetic components in some way contribute to 
the development of PE.
2, 110, 112, 113, 115
 In total, over 170 genes have been related to PE 
and HELLP syndrome, but no definitive conclusions have been drawn, probably 
because the genetic mechanisms in PE are complex and diverse.
115
 However, it has 
been shown that a woman who becomes pregnant with a man who has fathered a 
previous PE pregnancy in another woman has an increased risk for PE.
116
 Studies have 
also shown that both males and females, whose mothers had PE, have an increased risk 
for PE in their pregnancies.
111, 117
 
 
What effect the genes have on PE is unknown, but it is likely that they are involved in 
the interface between the mother and fetus.
2
 In the placenta, the fetal trophoblasts that 
invade the maternal tissue meet cells of the maternal immune system, amongst others 
NK cells, which recognize fetal polymorphic human lymphocyte antigens-C (HLA-C). 
In vivo studies have shown that certain combinations of HLA-C haplotypes and 
receptors on the NK cells are associated with an increased risk for PE
74
. Hiby et al
118
 
concluded that some combinations of paternal and maternal innate immunity genes 
were unfavorable for placentation. This might explain part of the disease. 
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2.3.4 Doppler ultrasound 
An abnormal transformation of the spiral arteries most probably underlies the 
circulatory dysfunction seen in PE and fetal growth restriction. Since the 1980’s 
Doppler ultrasound measurements have been increasingly used to obtain additional 
information regarding the impact of PE on the fetus and in the screening of maternal 
hypertension.
119-124
  
 
Today, it is known that abnormal umbilical artery Doppler findings are associated with 
fetal hypoxia, fetal acidosis and adverse perinatal outcome. Measurement of the blood 
flow in the umbilical artery is now used in order to improve perinatal outcome in 
pregnancies complicated by PE and fetal growth restriction.
125
 Normally, at 
approximately twelve weeks of gestation not only a systolic blood flow is present in the 
umbilical artery, but also a diastolic. From then on, the diastolic blood flow increases, 
but in the presence of malfunctioning villi, an increased resistance in the placenta does 
not permit this increase. As a result, the diastolic component decreases, become absent 
or even worse: reverse. The abnormal blood flow is then classified as absent end 
diastolic flow (AEDF) or reversed end diastolic flow (REDF).
126
 
 
Other vessels have also been investigated.
127-131
 Impaired trophoblast invasion into the 
spiral arteries has been related to abnormal uterine artery blood flow.
132, 133
 A normal 
trophoblastic invasion results in a physiological decrease of resistance of the uterine 
artery. In the absence of trophoblast invasion the decrease of resistance does not occur. 
Hence, measurement of blood flow in the uterine artery is used in order to find 
pregnancies complicated by fetal growth restriction and PE. Abnormal blood flow of 
the uterine artery has also been related to IUFD and abruption.
127
  
 
Nonetheless, the usage of uterine artery blood flow in screening for PE is not entirely 
reliable and several researchers have tried to find maternal serum markers in the 
screening for PE.
134, 135
 None has been found to anticipate PE, but an early PE could be 
predicted with the use of both Doppler measurements and a combination of several 
biomarkers.
134
 Apparently, screening of women with risk factors was actually less 
successful than screening of low-risk individuals.
134
 This could indicate that women 
with cardiovascular risk factors were likely to develop a maternal PE, whereas women 
without risk factors developed a placental PE as a consequence of an impaired 
placentation.
4, 9, 134
 
 
Some placental pathology has also been related to umbilical and uterine artery blood 
flow. Higher resistance in the umbilical artery has been related to fewer blood vessels 
in the villi 
136, 137
 and more placental infarction.
138-140
 Also abnormal uterine artery 
blood flow has been associated with placental ischemia.
139
    
 
2.3.5 Treatment for PE 
There is no other curative therapy of PE than induction of labor, which is a difficult 
decision in earlier pregnancies. At term, both mild and severe PE should be managed 
by induction of labor 
9, 141
, but before gestational week 34 expectant monitoring 
benefits the child, if possible due to the clinical situation of the mother.
142
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If induction of labor is chosen, suggested routes of delivery depend on gestational age 
and fetal and cervical status.
9
 If expectant monitoring is chosen, antihypertensive agents 
should be considered. No specific antihypertensive drug is preferred and the 
recommendation is to use one that the clinician is familiar with.
9
 Magnesium sulfate 
should be administered in severe PE patients to reduce the risk of eclampsia and in 
patients who have already developed eclampsia. Further, low-dose aspirin has been 
shown to decrease the risk for PE, but the numbers needed to treat is large and this is 
only recommended in high risk patients.
9
 More recently, studies have examined the 
effect of Heparine, which was shown to decrease the risks for PE and eclampsia, but as 
information on adverse outcome of the offspring is unavailable, more studies need to be 
performed.
143, 144
 As some pathology in PE is similar to arteriosclerosis and those 
disorders share many risk factors, trials on statins are also conducted.
145
  
 
2.3.6 Consequences of PE for the infant 
PE-infants are often growth-restricted, have a higher risk for IUFD and are more often 
born premature, which is itself a great risk factor for adverse outcome, as the next 
section will outline.
9, 10, 74, 146
 It seems as if PE-infants also need neonatal intensive care 
in a greater extent 
147-149
, but studies on neonatal morbidities have not been very 
convincing and often show contradicting results.
147, 150-156
 However, PE might be 
protective against retinopathy of prematurity (ROP).
157
 A couple of studies have 
showed a lower intelligence quote in PE children
155, 158
, but others have shown that PE 
is not related to special needs.
159
 Maybe, induction of labor also has an effect on the 
outcome of the infant.
160
 
 
In adulthood, children born to mothers with PE are shown to have higher blood 
pressure and higher body mass index (BMI) in adulthood.
161, 162
 The effect on body 
weight appears to be true also when excluding the effect of low birth weight, which can 
result in catch-up growth.
163
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2.4 PREMATURITY 
2.4.1 Definition 
Preterm birth is a delivery before 37 completed weeks of gestation. In addition, very 
preterm birth is defined as a birth before 32 gestational weeks and extremely preterm 
birth is a delivery before 28 gestational weeks.
164
 
 
2.4.2 Etiology 
Preterm birth can be divided into three categories. Firstly, about one third (30%) of the 
preterm births are caused by induction of labor, often because of fetal growth-
restriction, fetal demise or maternal hypertension. The remaining two thirds are 
spontaneous preterm births, which are divided into spontaneous preterm labor (45% of 
preterm births) and preterm premature rupture of the membranes (PPROM) (25% of 
preterm births). A spontaneous preterm labor is defined as a preterm onset of regular 
contractions and change in cervical status, whereas PPROM is defined as spontaneous 
preterm rupture of the membranes at least one hour before onset of contractions.
71, 165
  
 
The exact mechanisms behind spontaneous premature birth are unknown, and it is seen 
as a syndrome caused by several factors. Risk factors such as infection, inflammation, 
stress, uterine distension (as in multifetal gestation and in extremes in volume of 
amniotic fluid), low pre-pregnancy BMI, previous preterm birth, tobacco use, close 
interval between pregnancies and assisted reproduction (both in single and multiple 
pregnancies) have been identified.
165
 
 
2.4.1 Epidemiology 
The incidence of prematurity is around 12-13% in the United States and has risen 
during the last years.
165
 The main contributing factor is an increase in induction because 
of fetal or maternal reasons, such as growth restriction and PE. An additional factor is 
the increasing use of assisted reproduction technology.
165
 However, the incidence 
varies depending on geographic area
166
 and in Sweden there were 5.5% premature 
deliveries during 2011.
167
  
 
2.4.2 Consequences of prematurity for the infant 
Infants born premature are at increased risk for morbidities such as bronchopulmonary 
dysplasia (BPD), ROP, intraventricular hemorrhage (IVH), PVL and necrotizing 
enterocolitis (NEC).
71
 Those are described further in the following section. 
 
Several research groups have studied children born preterm and compared today’s 
outcome with survival and morbidity from previous years.
10, 11, 168-170
 The survival rate 
is increasing, but some of the major morbidities are shown to be the same as 
previously.
10
 The neurodevelopment is often lower
169, 170
 and Moore et al
11
 have shown 
an increase in developmental scoring with gestational age in infants born before 
gestational week 27. Nowadays, the incidence of CP is reported to be 7-14%.
11, 170
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2.5 THE OFFSPRING  
2.5.1 The normal scenario 
2.5.1.1 Intrauterine development 
Human gestation is about nine months long and often divided into three periods, the 
trimesters. In week 3-8 during the first trimester the organs and systems are formed. 
With the exception of the heart and the vasculature systems, most organs are not 
functional at that time. In the second trimester the organs continue to develop, but some 
organs, such as the reproductive organs and the brain do not mature fully until years 
after birth. In the last trimester the lungs mature and the majority of the weight gain 
occurs.
12
  
 
While living inside the maternal uterus, the infant is dependent on the maternal supply 
of oxygen and nutrients, but also on the maternal immune system’s ability to allow the 
presence of another individual. Teratogens and microbial pathogens might also cross 
the placenta and affect the unborn child. Another important factor for the infant’s well-
being is the balance of the amount of amniotic fluid.
12
 
 
From the start of the third trimester until term, the infant grows from less than 1 
kilogram to about 3.5 kilograms. During gestation, the body proportions also change: at 
nine weeks the head is half the crown-rump length, but at birth it is a quarter of the 
same length.
12, 171
   
 
At birth, it is essential that the infant starts breathing, which is stimulated by 
accumulation of CO2 and lack of O2, but also by the compression of the thorax during 
delivery. After birth, fluid in the neonatal lung is exchanged for air and soon the infant 
breathes regularly. In the delivery room, assessment of the newborn is important in 
order to identify infants in need of resuscitation. The acid-base status of the umbilical 
cord blood is examined. Additionally, Apgar scores are measured at 1, 5 and 10 
minutes of age and parameters evaluated are heart rate, respiratory effort, muscle tone, 
reflex irritability and color. 
71, 172
  
 
2.5.1.2 Childhood development 
As early as gestational week 20, the fetus starts to respond to auditory stimuli with a 
change in heart rate or by moving.
173
 Apparently, it can also distinguish between 
different sounds such as language and music.
173
 The newborn’s preference of sound is 
voices, and then, especially the voice of the mother.
12, 173
 During the first half year of 
life, the infant enjoys making noises and laughs and after a little more than a year, it 
starts to make specific sounds to the parents.
174
 
 
Just as the sound preference is voices, the visual preference is faces.
174
 During the first 
year of life, the child’s visual acuity, ability to move the eyes together and to focus at 
different distances are improved and already at the age of about 4 years, adult level of 
visual acuity is reached.
174
 Fine motor function develops together with vision, and at 
ten months of age, half of them use the pincer grip and at 1.5 years of age, they begin to 
draw with a crayon.
174
 The limit age for walking is 18 months, which is when only 
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2.5% still have not learned to walk and should be examined further, although many of 
them will not have any underlying problem. 
 
The first 5 years of life is the period when the child development occurs, with a 
remarkable improvement in motor function, language, hearing and visual development. 
However, preschool children do think that they are the center of the world, non-living 
objects are alive and have feelings, and that events are magic. Much of the cognitive 
development occurs at school age and although a small child develops sensitivity to 
communicative intentions, the understanding of irony is developed much later.
174-176
 At 
school age the major part of cognitive development, including abstract thinking and 
skills of conceptualization take place.
174
  
 
2.5.2 Adverse outcome 
2.5.2.1 Fetal growth restriction 
There are several definitions of intrauterine growth restriction, but it is often assumed 
when the infant is born small for gestational age (SGA), as compared to being 
appropriate for gestational age (AGA). SGA is sometimes defined as a birth weight less 
than the 10
th
 or the 5
th 
percentile.
177
 In Sweden, the diagnosis of SGA is defined as a 
birth weight lower than 2 SD below the mean.
178
 Additionally, some researchers have 
defined a birth weight less than 2.5 kilograms as evidence of growth restriction.
24
  
 
Risk factors for fetal growth restriction is use of tobacco, alcohol, narcotics, cocaine, 
undernutrition, but also fetal infection, chromosomal abnormalities, multiple gestation, 
pregnancy at high altitude, PE and other maternal diseases such as renal disease, 
maternal cyanotic heart disease, antiphospholipid syndrome and systemic lupus 
erythematosus.
72, 102, 177
   
 
Fetal growth restriction can be symmetrical or asymmetrical. An earlier impact, in the 
first months, often by chromosomal error, teratogens or infection, can give rise to a 
symmetric restriction, defined by the proportional growth restriction of all organs. It is 
thought that the number of cell divisions is decreased, thereby influencing all organs 
equally. On the other hand, a later impact, in the second half of pregnancy, often results 
in an asymmetric growth restriction. The infant is deprived in oxygen and nutrients and 
autoregulation redirects the blood flow to the brain. The prioritization of the brain 
results in a larger head in proportion to the abdomen and a higher brain to liver weight 
ratio. The underlying mechanism in asymmetric growth restriction is most often some 
form of placental insufficiency.
24, 71, 177
  
 
One problem with using growth restriction and SGA synonymously is that some infants 
are constitutionally small and not growth restricted. Furthermore some infants that are 
constitutionally large will not be regarded as growth restricted even though they are. To 
overcome this issue, usage of customized growth curves has been proposed.
177
 Those 
growth curves take maternal ethnicity, maternal weight and height, infant sex and parity 
into account. It is valuable to exclude the constitutionally small and to include 
constitutionally larger, but growth restricted infants, as outcome is related to growth 
restriction and not to smallness.
177
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Abnormal Doppler examination of the umbilical artery is related to growth restriction 
and can be useful in distinguishing pathological growth restriction to constitutional 
smallness.
125, 177
 Also, measurements of blood flow in the fetal middle cerebral artery, 
the uterine artery, ductus venosus and the umbilical vein have been investigated in 
relation to growth restriction.
125, 127, 129
 
 
2.5.2.2 Fetal and neonatal death 
2.5.2.2.1 Intrauterine fetal death (IUFD) 
Stillbirth is defined as no signs of fetal life present at or directly after birth, after 
completed gestational week 22. Causes of IUFD can be divided into fetal, placental and 
maternal, which often interact with each other. Some causes or underlying etiologies 
are chorioamnionitis, malformations, growth restriction, placental abruption, 
hypertensive disorders and DM. In a quarter of the cases no cause can be identified.
71
  
 
The stillbirth rate is the number of stillborn infants per 1 000 live born and stillborn 
infants.
72
 In Sweden, the stillbirth ratio was 40 / 1 000 during the 19
th
 century and since 
the 1960’ies it has drastically decreased from 20 to around 5 per 1 000 at the new 
millennium. Many Sub-Saharan and South-Asian countries still have stillbirth rate 
around 30-40 per 1 000. However, despite obvious advancements in obstetric care, the 
rate of stillbirth in countries such as Sweden has remained essentially constant during 
the last 2-3 decades.
7
 
 
2.5.2.2.2 Neonatal death 
The neonatal period is defined as the first 28 days of life and hence neonatal mortality 
is the term that describes a newborn’s death within that period. Early neonatal death 
happens during the first week, while those occurring during week two to four are 
considered to be late. Perinatal death includes both stillborn infants and neonatal 
deaths. The neonatal mortality rate is the number of neonatal deaths per 1 000 live born 
infants, whereas the perinatal mortality rate is the number of stillborn infants and 
neonatal deaths per 1 000 live- and stillborn infants.
72
 
 
2.5.2.2.3 Infant mortality 
Infant mortality is the decease of a live born infant during the first year of life. The 
infant mortality rate is the number of live born infants who dies during the first year of 
life per 1 000 live born infants.
72
   
 
2.5.2.3 Neonatal morbidities 
2.5.2.3.1 Bronchopulmonary dysplasia (BPD) 
In the last trimester the fetal lungs prepare for the extrauterine environment, by 
producing surfactant which prevents the lungs from collapsing during expiration. The 
risks of developing BPD, oxygen toxicity disease and pulmonary hypertension are 
increased in premature infants.
72
 Depending on how much extra oxygen the infant is in 
need of and for how long, BPD is regarded as mild, moderate or severe.
179
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2.5.2.3.2 Retinopathy of prematurity (ROP) 
As the retinal vessels develop they are very sensitive to excessive oxygen, which often 
must be administered because of lung immaturity. As a consequence of hyperoxemia, 
the infant might develop ROP, which can result in blindness.
71
  
 
2.5.2.3.3 Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL)  
The germinal matrix capillary network in the brain is fragile in the preterm infant; the 
autoregulation is not fully developed, the matrix does not sufficiently support the 
vessels and the vessels easily burst in response to an increase in intravascular 
pressure
72
. As a consequence, preterm infants born before gestational week 32 are at 
increased risk for periventricular hemorrhage and IVH. The cause of IVH in preterm 
infants is however multifactorial and prognosis depends on extent of bleeding and 
location.
72
 Some of those hemorrhages resolve, but large lesions can result in PVL, 
which has been associated to CP.
72, 180, 181
 Of preterm infants weighting less than 1.5 
kilograms, 3.2% develop PVL.
182
 In diagnosing PVL, the presence of cysts is very 
informative regarding prognosis.
183
  
 
IVH is graded 1-4, where grade 1 is a subependymal hemorrhage, grade 2 an IVH 
without ventricular dilatation, grade 3 an IVH with ventricular dilatation and 4 an IVH 
with parenchymal hemorrhage. 
184
 Long term prognosis is adverse in infants with grade 
3 and 4.
182
 
 
2.5.2.3.4 Necrotizing enterocolitis (NEC) 
Another complication of prematurity is NEC, primarily affecting low-weight infants
72
. 
It is thought to be a consequence of bowel ischemia, prematurity and infection. 
Symptoms include bloody stool, bowel distension, ileus, and can progress to 
disseminated intravascular coagulation.
72, 182
 Out of preterm infants weighting less than 
2 kilograms, 3-4% develop NEC.
182
  
 
2.5.2.4 Cerebral palsy (CP) 
The definition of CP has changed during the years, and today CP is defined as a group 
of disorders affecting the development of posture and movement attributed to a non-
progressive lesion in early fetal or infant life, often accompanied with impairment in 
other functions.
185
 A spastic CP is described according to which part of the body that is 
affected, e.g. monoplegia, diplegia, triplegia, quadriplegia or hemiplegia. An 
extrapyramidal lesion is characterized by movement disorders and/or hypotonia.
182
  
 
Risk factors are prematurity, low birth weight, inflammation and genetical factors. It is 
only in about 10% that a hypoxic-ischemic event around birth can be identified.
186
      
 
2.5.2.5 Delayed development 
The etiology of mental retardation includes genetic causes, metabolic disorders, 
acquired brain injury, environmental causes, infections and maternal use of alcohol and 
drugs. In addition sociocultural factors play a role.
187, 188
 Genetic causes are more 
common in severe developmental delay, whereas environmental factors more often 
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cause mild retardation.
188
 Overall, prenatal factors are the most common causes of 
delayed development.
188
  
 
Development is measured related to the age of the child and is in many scoring systems 
presented as an index, where the child’s developmental age is divided by its 
chronological age. This is thereafter multiplied by 100 and a normal index is hence 
100.
182
  
 
Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) 
189
 is an 
individually administered developmental assessment for infants between one and 42 
months of age. Bayley-III contains five different domains (adaptive behavior, 
cognition, language, motor and social emotional) and each domain contains two or 
more sub-domains. Raw scores from each sub-domain are transformed to scaled scores 
in order to compare an individual’s performance with other children of the same age, 
and finally the scaled scores are combined into a composite score for each domain. 
 
2.5.2.6 Adult consequences of fetal life environment 
Life in utero can not only influence the infant in a short term, but has apparently an 
impact on the future health of the offspring as well.
190
 Barker, studying more than 
10 000 men in Hertfordshire found that a low birth weight is related to cardiovascular 
diseases, including stroke, hypertension and DM type II.
191
 In rat models fetal 
undernutrition has been related to hyperphagia in adult life and prenatal hypoxia with 
atherosclerotic changes in the offspring.
192, 193
  
 
Many have also studied the impact of intrauterine exposure of PE on diseases in 
adulthood, and a meta-analysis of more than 45 000 patients showed that intrauterine 
exposure to PE was associated with higher blood pressure and BMI of the offspring in 
adulthood.
163
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3 AIMS OF THE THESIS 
 
 
The overall aim of this thesis was to study the placental pathology in relation to 
maternal symptoms in PE and in relation to neonatal outcome and development.  
 
Specific questions in the studies were: 
 
1. Is there a correlation between placental pathology and the severity of PE?  
 
2. Do patients with severe PE with and without HELLP differ in regard to 
placental pathology and frequency of SGA?   
 
3. In infants from PE pregnancies, is there a relationship between placental 
pathology and neonatal outcome? 
 
4. In an extremely premature population, is there a relationship between placental 
pathology and neonatal outcome? 
 
5. In an extremely premature population, is there a relationship between placental 
pathology and neurologic outcome and development at 2.5 years of age?   
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4 MATERIAL AND METHODS 
 
4.1 PLACENTAL EXAMINATION 
Pathological variables examined in study I-II were primarily typical PE findings, as the 
purposes were to correlate placental pathology in PE with maternal symptoms in PE. In 
study III-IV, more pathology variables were studied in order to include their impact on 
the outcome of the offspring. This was essential especially in the last study, as its 
population was not a pure PE population.   
 
The placentas in study II was examined by two different perinatal pathologists: one 
perinatal pathologist from Karolinska Hospital, Stockholm and one from Free 
University Hospital, Amsterdam. In addition, they together re-reviewed approximately 
20% of the original slides in order to establish common criteria and reach consensus on 
the histological diagnosis. Macroscopic data was collected from the pathology reports.    
 
In study I, III and IV, all histological slides were reevaluated by one senior perinatal 
pathologist at Huddinge, who was blinded to outcome. Macroscopic data was collected 
from the pathology reports.   
 
At the Section of Perinatal Pathology at Karolinska University Hospital Huddinge, 
macroscopic and microscopic examinations of the placentas were performed as 
described below.  
 
4.1.1 Macroscopic examination 
In nearly all cases the placenta was sent fresh to the Section of Perinatal Pathology at 
Karolinska University Hospital Huddinge. Upon arrival, the first macroscopic 
examination was performed, regularly within 48 hours. Thickness and maximal and 
minimal diameter were measured and the placenta was inspected regarding shape, fetal 
and maternal surface, membranes and cord. Any abnormality was recorded, in some 
cases photographed and fresh frozen tissue was obtained in special cases. Thereafter the 
placenta was fixated as whole in formalin for approximately 8-10 days. During the 
second macroscopic examination, the placenta was trimmed (membranes and the 
umbilical cord were removed) and weighed. The placental weight was regarded as 
normal, low or high in relation to gestational age using a standard curve.
194
 The 
placentas were then sliced in 0.5-1.0 cm thick slices and eventual focal abnormalities 
were assessed regarding location, color and volume. This is the origin of the data on 
amount of infarction.  
 
Samples were taken for histological analysis from macroscopically normal placenta (2-
3), umbilical cord (1-2) and the membranes (1-2) as well as from any focal abnormality 
observed.          
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4.1.2 Microscopic examination 
Tissue samples from placenta, umbilical cord and membranes were embedded in 
paraffin and stained with Hematoxylin & Eosin according to standard procedures. The 
microscopic examination of those slides was repeated in study I, III and IV in a blinded 
fashion.  
 
Decidual arteriopathy was defined as fibrinoid necrosis of the spiral artery wall, often 
with dilation of the vessels, with or without the presence of acute atherosis (presence 
of foamy macrophages) or luminal thrombosis. 
 
Infarction was recognized as an area of ischemic necrosis of the villi. Fresh as well as 
older infarctions were recorded. Necrotic villi close to intervillous thrombosis and in 
areas of extensive intervillous fibrin deposition were not regarded as infarction. 
 
The presence of intervillous thrombosis was noted, similarly to the infarction. Fetal 
thrombosis was defined as thrombosis in the vessels in the umbilical cord, chorionic 
plate or in the stem villi. 
 
Histopathological abruption was classified as the presence of retroplacental 
hemorrhage. Additional signs could include intravillous hemorrhages (fresh abruption), 
hemosiderin pigment deposition or signs of ischemia in the vicinity of the clot (older 
abruption). In some of the studies we also included clinical abruption. 
 
Villous maturation was regarded as accelerated when more than 50% of the villi 
examined in microscopy were more mature than normal for that gestational week. 
Signs included in the evaluation were the size and configuration of the villi, the 
trophoblast layer as well as the architecture and size of the blood vessels within the 
villi. Area around infarctions was not evaluated regarding maturation. In the 
chronologically first study (study II), all cases were evaluated regarded accelerated 
villous maturation, but in the following studies we decided to only assess preterm 
placentas, as it would be impossible to decide whether a full term placenta became 
mature before term or at term.  
 
Chorioamnionitis was diagnosed histologically in the presence of polymorphonuclear 
leukocytes. We included all grades of inflammation, from leucocyte infiltration in 
subchorionic plate, to spreading to the chorion and the amnion, as well as microabcess 
formation and necrosis of the amniotic epithelium.  
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4.2 STUDY DESIGNS AND POPULATIONS 
Figure 9 illustrates the source populations, rather than the study populations, that the 
studies in this thesis aimed to investigate, and the relations between those populations.   
 
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. An illustration of the source populations of the studies included in this thesis.  
 
 
4.2.1 Study I 
This study was a case-control study, in which cases were divided into two groups: one 
with mild PE patients (n=41) and one with severe PE patients (n=116). We also had a 
control group to compare the two study groups with. Type and extent of placental 
pathology was compared between the groups. 
 
Cases were recruited from lists of patients with PE cared at Karolinska University 
Hospital Huddinge and whose placentas were referred for pathological examination at 
any pathology department in Stockholm. The mild and severe PE-diagnoses were 
verified by analyzing medical records and laboratory results from all patients.  
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4.2.1.1 Definition of the PE groups 
PE was defined as a blood pressure of 140 mmHg systolic and/or 90 mmHg diastolic or 
higher on two occasions at least six hours apart and proteinuria, defined as, or 
analogous to, an excretion of 0.3 grams protein or higher in a 24-hour urine specimen. 
 
Severe PE was diagnosed when the systolic blood pressure reached 160 mmHg, the 
diastolic 110 mmHg or the proteinuria 5 grams/24-hour sample, but also when the 
pregnancy was complicated by fetal growth restriction or HELLP syndrome. This is in 
accordance to the criteria set by the American College of Obstetricians and 
Gynecologists.
65
 
 
4.2.1.2 The control group 
Our inclusion criterion for the patients in the control group was solely that the 
pregnancy should not be complicated by hypertension. They were selected from a list 
of placentas sent to the Division of Pathology department between 2004 and 2006 and 
picked consecutively if fulfilling the criteria. They were matched according to 4 
different gestational age groups.  
 
4.2.2 Study II 
This was a cohort study consisting of 178 severe PE patients, who were divided into 
two cohorts: one with HELLP syndrome (n=82) and another without HELLP (n=96). 
Those were compared regarding type of placental pathology. Also frequency of SGA 
was compared.  
 
Cases were recruited from lists of patients with PE cared at Karolinska University 
Hospital Huddinge and whose placentas were referred for pathological examination at 
any pathology department in Stockholm. The PE- and HELLP diagnoses were verified 
by analyzing medical records and laboratory results of all patients. Also a Dutch 
material was gathered, as explained further below. 
 
4.2.2.1 Definition of the cohort 
Severe PE was defined as in study I. HELLP was defined as hemolysis, elevated liver 
enzymes and low platelets. Hemolysis was based on low serum haptoglobin levels < 
0.24gram/L and/or elevated lactic dehydrogenase levels > 600U/L. Elevated liver 
enzymes were defined as ALAT >70 U/l and/or ASAT>70 U/l. Low platelet count was 
regarded as ≤ 100.000 /µl. 
 
4.2.2.2 Swedish and Dutch material 
As HELLP syndrome is a rare disorder, we included HELLP-patients from Free 
University Medical Center in Amsterdam, The Netherlands, which was a referral 
hospital for HELLP patients in The Netherlands.    
 
In order to ascertain that the pathological examination at Free University Medical 
Center and Karolinska University Hospital Huddinge were the same, one senior 
pathologist from each hospital examined and diagnosed placentas together.  
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There was a difference in the method of placental weighing of the Swedish and Dutch 
material. In Free University Medical Center the pathologist weighed the placentas 
fresh, whereas the placentas at Karolinska University Hospital Huddinge were weighed 
after formalin fixation. As the placental weight changes after formalin fixation
195, 196
 
and the Dutch placentas were part of one of the cohorts, there was a risk for 
confounding. Therefore, only the Swedish placentas were included when placental 
weight was compared.  
 
Birth weights were related to national growth curves. There were no differences in 
SGA between the Swedish and Dutch HELLP-patients, when the weights were related 
to the appropriate growth curve. Of the Swedish HELLP-cases, 6/21 (28.6%) were 
SGA and of the Dutch 13/60 (21.7%). However, actual birth weight was lower in the 
Dutch material.  
 
Before we mixed the Swedish HELLP-cohort with the Dutch, we compared them 
regarding several parameters (maternal smoking, frequency of SGA, accelerated villous 
maturation, decidual arteriopathy, infarction, intervillous thrombosis and abruption). As 
no statistical significant differences were found, we compared PE patients with the 
entire HELLP cohort. One exception was analysis of placental weight, for which the 
Dutch material was excluded, as explained above. 
 
4.2.2.3 How many had only HELLP-symptoms? 
Of the HELLP patients, 24 (29.3%) had proteinuria fulfilling the criteria for severe PE. 
However, measurement of proteinuria was in many cases not done.  Regarding blood 
pressure, we have not recorded whether the pressure reached mild or severe level and 
we can therefore not report on that. Previously, hypertension or proteinuria has been 
reported to be absent in up to 15% of HELLP patients.
4
 
 
4.2.3 Study III 
This was a cohort study consisting of 544 infants born to PE mothers. The type and 
extent of placental pathology was correlated to neonatal outcome of the cohort. 
 
Patients were identified from the hospital's diagnostic database and included if the 
placenta had been referred to the Section of Perinatal Pathology at Karolinska 
University Hospital Huddinge.  
 
4.2.3.1 Ultrasound measurements of umbilical artery blood flow 
Often, additional ultrasounds are performed in PE patients. When those were available, 
we collected data on flood flow of the umbilical artery. An abnormal umbilical artery 
blood flow was defined as AEDF or REDF, or as a pulsatility index (PI) more than 2 
SD above mean at that gestational week.
119
 
 
4.2.3.2 Neonatal morbidity and mortality 
We choose to study the variable major neonatal morbidity, as many of the severe 
neonatal morbidities are rare and difficult to study in smaller materials. Major neonatal  
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morbidity was defined as IVH ≥grade 3, ROP ≥grade 3, NEC, cystic PVL and/or severe 
bronchopulmonary dysplasia. Additional outcome variables were IUFD, neonatal 
death, SGA, need of care at neonatal unit, delivery room assessment scores, need of 
mechanical ventilation and sepsis.  
 
Data on neonatal outcome was gathered from several sources: In 294 of the live-born 
infants, data could be found in PNQ (Perinatal Quality Registry), while data regarding 
227 was gathered from medical records. If data in PNQ was not complete, data was 
also collected from medical records. For example, if it was recorded that the infant 
suffered of BPD, but the % of Oxygen at 36 weeks was not specified, we went through 
the medical records to determine if the BPD was severe. Also, cases with sepsis were 
verified by analyzing the medical records. Data on ROP was gathered from the 
National Registry of ROP. 
 
4.2.4 Study IV 
This cohort study was different from the previous studies because it did not include a 
pure PE population, but an extremely premature population, comprising both PE and 
non-PE patients. The patients were part of the extremely preterm infants in Sweden 
study (EXPRESS). The placental pathology was related to both neonatal outcome as 
well as neurologic outcome and development at 2.5 years of age.  
 
The patients included were all live-born and stillborn infants born in gestational week 
22+0 - 26+6 in the Stockholm County during April 2004 – March 2007, where a 
placental examination was performed at any hospital. A placental examination was 
done in 79% of the patients. After excluding two placentas because of poor quality of 
the sample, 167 patients remained. 
 
4.2.4.1 Neonatal morbidity and mortality  
Variables studied in the neonatal period were almost the same as in study III. However, 
there was no interest in studying admission to neonatal care as all infants born <27 
weeks of gestational age are in need of neonatal hospital care. Data was collected from 
PNQ and if something was unclear or missing, medical records were analyzed. 
 
4.2.4.2 Neurologic outcome and development at 2.5 years of age 
Neurologic impairment was divided into severe neuromotor impairment, defined as CP, 
and severe neurosensory impairment, defined as severe hearing impairment (hearing 
loss that could not be corrected despite a hearing aid) and/or severe visual impairment 
(blind or only able to see torch light). 
 
At 2.5 years corrected age a Bayley-III tests were performed to evaluate developmental 
outcome.
189
 We have used a group of healthy term born Swedish children as a 
reference.
197
 A score more than 2 SD below the mean of their results was considered 
delayed, i.e. a composite cognitive score below 83, a composite language score below 
85, and a composite motor score below 80.  
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4.3 STATISTICS 
For demographic data we performed t-tests when analyzing continuous data that was 
normally distributed. If the data was not normally distributed we used the non-
parametric test Mann-Whiney U-test. For categorical data we performed Chi-square 
test and if >20% of expected frequencies were <5 or if any expected frequency was <1, 
we used Fisher’s exact test.  
 
4.3.1 Study I 
For analysis on binomial and multinomial outcome variables we used logistic 
regression analysis. Adjustment for gestational age was done when it was shown to 
affect the result. For placental weight in relation to gestational age we used chi-square 
test. In the regression analyses we first analyzed the effect on all groups and if it was 
significant we continued analyzing differences between the three groups. In order to 
compare three groups (mild PE, severe PE and controls) in the regression model, we 
used Dummy-variables.  
 
4.3.2 Study II 
When analyzing binomial and multinomial outcome variables we used logistic 
regression and when gestational age was shown to affect the result, gestational week 
was included in the analysis as a covariate.  
 
4.3.3 Study III 
For outcome variables, forward step-wise analyses were performed including all 
pathological variables and the gestational week. Including all variables in one analysis 
model was possible because of the larger number of patients compared to study I and II. 
Also, interactions were studied and further analyzed. When analyzing the more rare 
neonatal morbidities separately, we used Fisher’s exact test. 
 
4.3.4 Study IV 
For outcome variables we used forward stepwise analysis including variables that were 
significant in the univariate analysis. We did not include all pathological variables in 
the model analysis in order to keep events per variable preferably below 10.
198
 In 
addition to pathological variables also gestational age, presence of PE, obesity and 
maternal age were studied and included in the models if they showed a significant 
effect on the outcome. Also interactions were studied and included in the analyses 
when present.  
 
For analysis of the relations between pathology and neurologic and developmental 
outcome we used Fisher’s exact tests for categorical data as <20% of expected 
frequencies were <5 or any expected frequency <1. Regarding continuous development 
data, we performed a regression analysis (ANCOVA) including gestational age in the 
analysis. The data on placental weight did not fulfill the criteria for a regression 
analysis and was performed with a non-parametric test.  
 
   37 
4.4 ETHICS PERMISSION 
For the first three studies, ethic approvals to perform the studies without contacting the 
patients were given from the Regional Research Ethics Board in Stockholm, Sweden. 
All patients that had their placenta sent to the division of pathology gave their informed 
consent to save the placental tissues according to the bio bank law. Tissues from 
patients who disapprove are destroyed after examination and histopathology slides are 
not stored in those instances. According to Dutch law, no ethics permission was needed 
for the Dutch material included in study II.    
 
For study IV, ethics approval was given from the Regional Ethics Review Board in 
Lund, Sweden. The reason why the Board in Lund was engaged was that the study was 
part of a nationwide study that the Review Board in Lund gave its approval to. The 
parents gave their written consent for data acquisition and for examination of their 
children. 
 38 
5 RESULTS 
 
5.1 STUDY I 
The 157 PE patients were diagnosed with PE at mean gestational week 33 and 
delivered at mean gestational week 35. The gestational weeks at diagnosis and delivery 
were later in the 41 mild PE patients (diagnosis in week 36 and delivery in week 37) 
than in the 116 severe PE patients (diagnosis in week 33 and delivery in week 34) 
(p<0.001).  
 
The non-PE group (controls) consisted of patients without any hypertension in their 
pregnancies and they were matched to the PE-patients according to gestational age 
group. Many of them were premature and admitted for placental examination for other 
pathological reasons than hypertension in pregnancy. Infection was found in 27% and 
abruption in 23% of the patients in the non-PE-group. Also, growth restriction (17%) 
and stillbirth or neonatal deaths (12%) were relatively common reasons for referral. 
Whereas stillbirth was more common in the non-PE group (11.5%) than in the PE 
group (3.2%) (p<0.01), SGA-infants were less common in the non-PE-group (29.3%) 
than in the PE-group (47.8%) (p<0.001).   
 
5.1.1 Placental pathology 
There were significant differences between mild and severe PE patients in relation to 
the non-PE group regarding infarction (p<0.001), decidual arteriopathy (p<0.001) and 
accelerated villous maturation (p<0.001), as is illustrated in figure 10. No differences 
were found regarding intervillous thrombosis or abruption. When comparing mild and 
severe PE patients a difference could only be found in the occurrence of infarction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Placental pathology in the severe PE-, mild PE- and non-PE-group (controls) in study I. 
 
When studying the degree of infarction we found significant differences between the 
non-PE group and the two PE-groups (p<0.001), but also between the mild and severe 
PE groups (p=0.015). Se figure 11.  
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Figure 11. Amount of infarction in the severe PE-, mild PE- and non-PE-groups (controls) in study I. 
 
Regarding placental weight, there were no significant differences in the weights in 
relation to gestational age between the mild PE patients, the severe PE patients or the 
non-PE patients.  
 
5.1.2 Sub groups 
According to current diagnostic criteria, PE is regarded as severe when the mother has 
severe hypertension, severe proteinuria, HELLP syndrome or when the infant is growth 
restricted. In the severe PE group, 43 cases had both severe maternal symptoms and a 
SGA-infant. In 42 women, the criteria for severe PE were fulfilled without a SGA-
infant. In 31 cases, the babies were SGA although the maternal symptoms were at a 
mild PE level. According to the above criteria, all those were severe PE. Some aspects 
of placental pathology in the sub groups of severe PE and in mild PE and non-PE are 
presented in figure 12.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Placental pathology in sub groups of severe PE, mild PE and non-PE-patients in study I. 
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5.2 STUDY II  
Patient demographics did not differ significantly between the 117 PE patients without 
HELLP syndrome (PE-group) and the 82 severe PE patients with HELLP syndrome 
(HELLP-group), with the exception of gestational week. Mean gestational week at 
delivery was 34 in the PE group and 32 in the HELLP-group (p=0.004). The time 
between diagnosis and delivery was slightly shorter (about half a week) in the HELLP-
group (p=0.06).   
 
5.2.1 Placental pathology 
In the PE-group, there were significantly higher frequencies of infarction (p=0.014), 
intervillous thrombosis (p<0.001) and abruption (p=0.002) compared to the HELLP-
group, see figure 13. There were no significant differences in accelerated villous 
maturation or decidual arteriopathy.  
 
In this study, originally all cases were included in the analysis of accelerated villous 
maturation. When excluding term placentas (14 PE-cases and 12 HELLP-cases), 
accelerated villous maturation was present in 72.1% of the PE-patients and in 81.4% of 
the HELLP-patients, as is seen in figure 13. Excluding term cases did not change the 
result (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Placental pathology in PE- and HELLP-patients in study II. 
 
 
5.2.2 Placental weight 
The mean placental weight in the PE-group was 310.5 gram and in the HELLP-group 
391.6 gram (p<0.001). Regression lines for placental weight in the two groups 
according to gestational age are presented in figure 14. When studying the placental 
weight in relation to gestational age according to a standard curve, there were 
significantly more high placental weights in the HELLP-group (p=0.016).     
 
One placenta had an extreme weight of 1008 gram, and was also reported to be hydrops 
fetalis. That case was excluded when calculating the mean placental weight as well as 
in the regression analysis. 
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Figure 14. Regression lines for placental weight according to gestational age in PE- and HELLP-patients 
in study II.  
 
5.2.3 Birth weight 
There was a significant difference (p<0.001) in frequencies of SGA-infants between the 
groups. In the PE-group, 71.9% were SGA and in the HELLP-group 23.5%. Mean birth 
weight, adjusted for gestational age was 1562.7 grams in the PE-group and 1672.1 
grams in the HELLP-group. The difference in birth weight was dependent on 
gestational age. In gestational week 30, the difference was not significant, but in week 
33 it was (p=0.03). In week 36, the difference was even larger (p<0.001). 
 
5.3 STUDY III 
Out of the 544 PE patients, 172 women gave birth very preterm (before gestational 
week 32), 207 women delivered preterm (between gestational week 32 and 37) and 165 
women at term (from gestational week 37).  
 
5.3.1 Placental pathology 
Placental pathology of the entire population is presented in figure 15. The most 
common findings were accelerated villous maturation (evaluated in preterm cases) 
(73.1%), intervillous thrombosis (32.7%), decidual arteriopathy (28.7%) and infarctions 
involving ≥5% of the placenta (17.1%).      
 
 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Placental pathology in the study cohort in study III. 
 
 
5.3.2 Umbilical artery blood flow 
Measurement of the umbilical artery blood flow was performed in 317 women. It was 
abnormal in 113 (35.6%). Regression analysis on associations between placental 
pathology and blood flow is presented in table 3. An abnormal umbilical artery blood 
flow was related to ≥5% placental infarction and a low placental weight (adjusted odds 
ratio (OR) 4.7, 95% confidence interval (CI) [1.9-12], p<0.001; adjusted OR 4.3, 95% 
CI [2.2-8.5], p<0.001; respectively), whereas intervillous thrombosis and accelerated 
villous maturation were inversely related to abnormal umbilical artery blood flow 
(adjusted OR 0.46, 95% CI [0.25-0.85], p=0.01; adjusted OR 0.39, 95% CI [0.17-0.91] 
p=0.03; respectively).  
 
Table 3. Regression analyses of placental pathology & umbilical artery blood flow 
 Adjusted OR (95% CI) Model p-value
a
 
Low placental weight 4.3 (2.2-8.5) <.001 
Accelerated villous maturation 0.39 (0.17-0.91) .04 
Decidual arteriopathy 0.76 (0.41-1.4) NS 
Infarction   
      <5% 1.5 (0.75-3.1) 
.002 
      ≥5% 4.7 (1.9-12) 
Intervillous thrombosis 0.46 (0.25-0.85) .01 
Fetal thrombosis 1.4 (0.51-4.1) NS 
Villitis 1.4 (0.63-3.3) NS 
Chorioamnionitis 0.75 (0.20-2.8) NS 
Gestational age, increase/week 0.71 (0.64-0.80) <.001 
OR, odds ratio; CI, confidence interval., 
a
Forward-stepwise model. 
 
 
5.3.3 Perinatal and neonatal outcome 
Fetal mortality was 4.2% (n=23) whereas neonatal mortality was 1.7% (n=9). The 
frequency of SGA-infants was 39.8% (n=216). Delivery room assessment showed a 5 
minutes Apgar score <4 in 1.3% (n=7) and <7 in 7.9% (n=41) of the live born infants. 
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Base excess (BE) of the umbilical artery was ≤-10 in 14.4% (n=41) of the infants and 
pH of the umbilical artery ≤7.10 in 6.9% (n=27). Data on BE and pH was not available 
in all infants.  
 
Admission to neonatal care differed depending on gestational age: all (n=151) infants 
born very preterm and the majority of the preterm infants (n=184, 89.3%) were 
admitted, in contrast to a minority (n=30, 18.3%) of the term infants. 
 
Major neonatal morbidity was found in 23 (15.2%) of the very preterm infants. Three 
of them had IVH ≥grade 3, nine had ROP ≥grade 3, ten had NEC, two had cystic PVL 
and four had severe BPD. Five of the infants had two major morbidities, but none had 
more than two. Of the very preterm infants 59 (39.1%) needed mechanical ventilation 
and 50 (33.1%) suffered from sepsis.  
 
5.3.4 Placental pathology and outcome 
Logistic regression analyses on associations between placental pathology and some 
neonatal outcome are shown in table 4.  Whereas infarction and chorioamnionitis were 
associated with a higher incidence of IUFD, accelerated villous maturation was 
associated with a lower one. SGA was associated with a low placental weight and 
infarction. Admission for neonatal care was associated with decidual arteriopathy and 
fetal thrombosis. For OR and p-values see table 4. No associations were found with 
need for mechanical ventilation or sepsis. 
 
Regarding delivery room assessment, chorioamnionitis was associated with Apgar 
score <7 at 5 minutes (adjusted OR 5.2, 95% CI [1.6-18]) and a low umbilical artery 
pH (adjusted OR 3.3, 95% CI [1.0-11]). Also infarctions ≥5% was associated with BE 
≤-10 (adjusted OR 5.4, 95% CI [1.8-16]).   
 
Major neonatal morbidity, which was evaluated in the very preterm infants, was 
associated with a low placental weight in relation to gestational age (adjusted OR 5.2, 
95% CI [1.1-24]). Also a high placental weight was associated with major neonatal 
morbidity (adjusted OR 1048, 95% CI (21-51663). None of the women with a large 
placenta had DM. The distribution of placental weight in relation to gestational week 
according to a reference curve in infants with and without major neonatal morbidity is 
presented in figure 16. No preterm large placenta (n=12) showed accelerated villous 
maturation, compared to 75.8% of preterm placentas with normal or small size (n=326) 
(Fisher exact test: p<0.001).    
 
When analyzing the major neonatal morbidities separately using Fishers exact test, 
accelerated villous maturation tended to be inversely related to IVH ≥ grade 3 (p=0.07). 
A low placental weight was associated with NEC (p<0.05), whereas a high weight 
tended to be related to cystic PVL and IVH ≥ grade 3 (p=0.05 and p=0.08, 
respectively). Decidual arteriopathy was associated with ROP ≥ grade 3 (<0.05), while 
infarction tended to be inversely related with ROP ≥ grade 3 (p=0.06).  
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Table 4. Placental pathology and perinatal outcome 
   IUFD  SGA  Admission to neonatal unit 
  Adjusted  
OR (95% CI) 
Model 
p-value
a
 
 Adjusted  
OR (95% CI) 
Model 
p-value
a
 
 Adjusted 
OR (95% CI) 
Model p-
value
a
 
Low placental weight  3.9 (0.71-21) NS  7.2 (4.5-11) <.001  0.97 (0.49-1.9) NS 
Accelerated villous maturation  0.18 (0.04-0.77) .04  0.82 (0.45-1.5) NS  5.1 (0.50-51) <.001
b
 
Decidual arteriopathy  1.9 (0.6-6.4) NS  1.3 (0.79-2.0) NS  2.7 (1.1-6.5) .04 
Infarction          
      <5%  11 (0.95-134) 
<.001 
 1.4 (0.85-2.2) 
<.001 
 0.83 (0.39-1.8) 
NS 
      ≥5%  75 (5.5-1011)  3.2 (1.7-5.9)  1.7 (0.63-4.8) 
Intervillous thrombosis  1.1 (0.31-4.0) NS  1.3 (0.87-2.1) NS  1.9 (0.96-4.0) NS 
Fetal thrombosis  0.37 (0.02-6.7) NS  1.2 (0.56-2.7) NS  2.4 (0.84-6.7) .02 
Villitis  3.1 (0.47-21) NS  1.6 (0.90-3.0) NS  1.8 (0.79-4.2) NS 
Chorioamnionitis  14 (1.6-125) .03  1.3 (0.60-3.0) NS  2.2 (0.78-6.0) NS 
Gestational age, increase/week  0.51 (0.39-0.67) <.001  0.91 (0.84-0.98) <.001  0.59 (0.45-0.78) <.001 
IUFD, intrauterine fetal death; SGA, small for gestational age; OR, odds ratio; CI, confidence interval. 
a
Forward-stepwise model; 
b
Accelerated villous maturation remained in the stepwise analysis because of the large number of full term placentas. When excluding  
those, there was no association (adjusted OR 5.1 [0.5-50.9], p=.18).
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Figure 16. Placental weight in relation to gestational age in infants with or without major neonatal 
morbidities in study III.  
 
5.4 STUDY IV 
Out of the 167 women giving birth to extremely premature infants, 13 were diagnosed 
with PE. Of the women with available weight and height, 54 (43.2%) were overweight 
and 22 (17.6%) were obese. Cesarean section was performed in 36 (21.6%) of the 
women. 
 
5.4.1 Placental pathology 
Placental pathology of the entire population is presented in figure 17. The most 
common findings were chorioamnionitis (61.7%), accelerated villous maturation 
(evaluated in preterm cases) (26.9%) and fetal thrombosis (19.8%). Of 13 women 
diagnosed with PE, 84.6% had accelerated villous maturation compared with 21.1% of 
the 154 without a PE diagnosis (p<0.001, Fishers exact test).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Placental pathology in the study cohort in study IV.  
 46 
 
5.4.2 Outcome of the offspring 
5.4.2.1 Perinatal and neonatal outcome 
Fetal mortality was 37.1% (n=62) and neonatal mortality 36.2% (n=38). Birth weight 
was SGA in 29 (18.5%) of the infants. At 5 minutes, 47 (45.2%) had an Apgar score 
<7. Major neonatal morbidity was found in 42 (40.0%) of the neonates. 
 
5.4.2.2 Neurologic outcome and development at 2.5 years of age 
Information on CP was available in 58 children, and of them three were diagnosed with 
CP. None had severe visual or hearing impairment.  
 
At 2.5 years corrected age, 50 were examined regarding cognitive (n=50), language 
(n=49) and motor (n=48) development. Mean Bayley-III cognitive score was 96.00 (SD 
8.3) and of these one (2.0%) fulfilled the criteria for a delayed cognitive development. 
Looking at language development, mean Bayley-III language score was 96.51 (SD 
14.4). Seven (14.3%) of them had a delayed language development. When studying 
motor development, mean Bayley-III motor score was 101.29 (SD 17.2) and five 
(10.4%) of them had a delayed motor development. 
 
5.4.3 Placental pathology and outcome of the offspring 
5.4.3.1 Placental pathology and neonatal outcome 
Fetal thrombosis and low placental weight were associated with both IUFD and SGA 
infants. Chorioamnionitis was associated with a lower frequency of SGA. Accelerated 
villous maturation was associated with better Apgar score at 5 minutes. For OR and p-
values se tables 5-7. Major neonatal morbidity and neonatal mortality was not 
significantly associated with any placental pathology variable.  
 
Table 5. Regression analyses of placental pathology and Apgar <7 at 5 minutes  
 Univariate analysis  Model analysis 
 p-value Crude  
OR (95% CI) 
 p-
value* 
Adjusted  
OR (95% CI) 
Abruption .92 0.96 (0.43-2.1)  - - 
Accelerated villous 
maturation 
.0046 0.23 (0.085-0.64)  .041 0.33 (0.12-0.96) 
Chorioamnionitis .32 1.5 (0.66-3.5)  - - 
Decidual arteriopathy - -  - - 
Fetal thrombosis .45 0.63 (0.20-2.0)  - - 
Infarction .11 0.27 (0.055-1.4)  - - 
Intervillous thrombosis .81 1.2 (0.24-6.4)  - - 
Low placental weight .72 0.82 (0.29-2.4)  - - 
Obstetrical data:    -  
Gestational week <.001 0.52 (0.37-0.73)  <.001 0.56 (0.40-0.79) 
Obesity .85 0.90 (0.30-2.7)  - - 
Maternal age .82 0.99 (0.93-1.1)  - - 
PE .25 0.38 (0.07-2.0)  - - 
* Forward-stepwise model 
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Table 6. Regression analyses of placental pathology and IUFD  
 Univariate analysis  Model analysis 
 
p-value 
Crude  
OR (95% CI)  
p-
value*§ 
Adjusted  
OR (95% CI) 
Abruption .049 0.49 (0.24-1.0)  .089 0.61 (0.27-1.4) 
Accelerated villous 
maturation 
.92 1.0 (0.51-2.1)  - - 
Chorioamnionitis .041 0.51 (0.27-1.0)  .26 - 
Decidual arteriopathy .0087 3.7 (1.4-9.9)  .16 - 
Fetal thrombosis .0080 2.9 (1.3-6.3)  <.001 5.3 (2.0-13.8) 
Infarction .075 2.3 (0.92-5.6)  .34 - 
Intervillous thrombosis .11 2.4 (0.81-7.4)  -  
Low placental weight .0068 2.8 (1.3-5.9)  .011 4.2 (1.7-10.3) 
Obstetrical data:      
Gestational week <.001 0.66 (0.52-0.83)  <.0001 0.53 (0.39-0.71) 
Obesity .18 0.48 (0.16-1.4)  - - 
Maternal age .99 1.0 (0.94-1.1)  - - 
PE .92 1.1 (0.33-3.4)  - - 
* Forward-stepwise model, § Including interactions  
 
 
Table 7. Regression analyses of placental pathology and SGA 
 Univariate analysis  Model analysis 
 p- 
value 
Crude  
OR (95% CI)  
p-
value* 
Adjusted  
OR (95% CI) 
Abruption .023 0.27 (0.09-0.84)  .29 - 
Accelerated villous 
maturation 
.053 2.3 (1.0-5.4)   .54 - 
Chorioamnionitis <.001 0.20 (0.08-0.47)  .014 0.25 (0.08-0.74) 
Decidual arteriopathy .011 3.7 (1.3-10.1)  .51 - 
Fetal thrombosis <.001 4.7 (1.9-11.2)  <.001 7.2 (2.2-22.9) 
Infarction .0054 4.0 (1.5-10.5)  .56 - 
Intervillous thrombosis .24 2.1 (0.6-7.4)   - - 
Low placental weight <.0001 13.7 (5.3-35.1)  <.001 8.7 (2.8-27.6) 
Obstetrical data:      
Gestational week .037 1.4 (1.0-1.8)  .94 - 
Obesity .94 1.0 (0.31-3.5)   - - 
Maternal age .30 1.0 (0.97-1.1)   - - 
PE <.0001 14.0 (3.9-49.6)  .033 5.1 (1.1-23.0) 
* Forward-stepwise model 
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5.4.3.2 Placental pathology and neurologic outcome and development at 2.5 years 
Firstly, placental infarction showed a significant association with a diagnosis of CP 
(p=0.036). Furthermore, placental abruption showed a tendency to be associated with 
CP (p=0.061). 
 
Of the 34 children with normal villous maturation, 7 (20.6%) were classified as being 
delayed with their language development, whereas none of the 15 children with 
accelerated maturation had a delayed language development. The difference did not 
reach the significance level, but showed a tendency (0.084). 
 
Fetal thrombosis showed a tendency to be related to a lower cognitive development 
(mean 91.7, SD 8.7) compared with children without fetal thrombosis (mean 97.0, SD 
8.0). After adjustment for gestational age the difference still did not reach a significance 
level, but showed a tendency (p=0.055). Including sex in the analysis did not change 
the result (data not shown).  
 
Lastly, infants with a low placental weight showed a mean Bayley-III composite motor 
score of 92.0 (SD 15.1), compared with children without a low placental weight whose 
mean Bayley-III composite motor score were 103.4 (SD 7.1). This tended to be 
significant (p=0.051), when analyzed with a non-parametric test. A regression analysis 
was not performed as the data did not fulfill the criteria for such analysis.  
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6 DISCUSSION  
 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study designs 
The studies included in this thesis are all observational cohort- or case-control studies. 
Some of them are retrospective, others prospective. The two first studies are solely 
retrospective.  
 
One disadvantage with retrospective studies is the dependence on information that is 
available. It is impossible to go back in time and reexamine the sick patient, study the 
placenta macroscopically again, take any additional laboratory tests or add any other 
information that is lacking in the medical record.  
 
In the second study, two different perinatal pathologists examined the placentas 
histologically and were not blinded to study group. Their evaluations of the placentas 
might have differed, which could have influenced the results as they examined different 
proportions of the study groups. An attempt to minimize this problem was done by 
letting the pathologists examine several cases together. In addition, the pathologists 
who examined the placentas could have been prone to find certain pathological features 
depending on study group, as they were not blinded. Further possible misclassifications 
are discussed under the section misclassification. 
 
In the first study (chronologically the second), we tried to overcome some of the above 
issues by letting one experienced perinatal pathologist reexamine all histopathological 
slides of placental tissue, blinded to study group. However, the macroscopic data could 
not be reexamined. 
 
In the first study, we also included a control group. Recruiting a control group to this 
sort of study population is complicated. The morphology of the placenta changes with 
gestational week, thus the inclusion of healthy term placentas as controls is obviously 
suboptimal. It is therefore desirable to find a healthy control group of the same 
gestational age. However, recruitment of such an ideal control group is unachievable, 
since the overwhelming majority of placentas from preterm pregnancies are referred to 
pathologic examination because of a pregnancy complication. In the choice between 
two suboptimal control groups, we used placentas from all gestational weeks, not 
complicated by hypertension, but by other disorders. It is nonetheless important to 
remember the type of reference group when drawing conclusions from the results. No 
differences could be found regarding intervillous thrombosis and abruption, which 
could be explained by the non-ideal control group. 
 
The two last studies were mainly prospective cohort studies. Although some data was 
gathered retrospectively (depending on which year between 2000 and 2009 the infant 
was born), the cohorts were identified before knowledge of the outcome. Also, in those 
studies, one senior perinatal pathologist examined the placental pathology, blinded to 
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outcome. The outcome data was gathered from medical records and data registries, as 
well as from the prospective follow-up of children at 2.5 years of age. 
  
One disadvantage of the last two studies is that some of the neonatal morbidities and 
developmental variables are rare. In order to find associations, the study groups must be 
very large. To compensate for that, we chose to study more frequent variables too, as 
well as a commonly used composite variable, including the most severe diseases in the 
neonatal period. In order to study associations with the rare diseases separately, case-
control studies would be more suitable. 
 
6.1.2 Type I and type II errors 
Thanks to statistical analyses, we drew conclusions on whether differences or 
associations were likely to be true or not. However, it is possible to draw the wrong 
conclusion. Assuming there is an association (p-value <0.05), when it is not true, one 
makes a type I error.
199
 Choosing a significance level at p <0.05 means that there is a 
95% probability that the result is true, when the p <0.05. However, there is also a 5% 
probability that it is not. Performing 100 analyses, 5 of them will show significant 
associations without actually being true associations. In our studies we have performed 
many analyses and the risk of type I error is high. In this thesis, there are in total about 
35 associations or differences with a significance level at p <0.05. Out of those, 5%, 
hence 1 or 2, are perhaps type I errors.  
 
On the other hand, to assume that there is no association (p-value >0.05), when there 
actually is one, represents a type II error.
199
 This is common when lacking power, 
meaning that there are too few cases in order to note a difference or an association that 
actually is true. This can also have occurred in our studies, as the number of cases 
included was limited to the placentas referred for pathological examination.     
 
6.1.3 Biases 
Biases are systematic errors resulting in wrong conclusions. Making a study larger does 
not minimize this type of error, but if one identifies possible biases one can design a 
study to avoid them. Bias is often divided into information bias, confounding and 
selection bias.
200
 Information bias will be dealt with under the title misclassification.  
 
6.1.3.1 Missclassification of placental pathology 
The placental feature decidual arteriopathy is a focal finding located at the maternal 
side of the placenta, not all of which is included in the specimen sent for pathologic 
examination. If not enough decidual arteries are represented in the placental specimen, 
the pathologist might not detect the arteriopathy although it was present in the maternal 
vessels. The frequencies of arteriopathy differed between 22-35% in the PE groups we 
studied. Gerretsen et al
201
 showed absent physiological changes of the spiral arteries in 
97% of cases in a PE population. Also, Meekins et al
16
 found atherosis in the decidual 
arteries of 92% of their PE patients. They both, compared to us, studied biopsies taken 
from the placental bed after delivery.  
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It is therefore likely that this feature is underestimated in our studies. However, as the 
examination of the placenta follows a structured manual and as most of the studies were 
blinded, there should not be any difference of this type of error in placentas from 
different groups. Hence the type of error is what is called non-differential and there is a 
risk to underestimate the frequency in any group, making it more difficult to find a 
difference or an association that actually is present.  
 
There is a physiological maturation of the villi with gestational age and the exact 
estimation of maturation of the villi has been shown to be difficult. A difference of up 
to 6 gestational weeks can remain undetected
202
. A previous study
202
 showed that the 
pathologists tended to overestimate the age of early gestations and underestimate the 
age of later gestations. Anyhow, this error will be equally common in all groups, again 
non-differential. An exception is study I in which mild PE, more often late, is compared 
to severe PE, more often early. Another difficulty regarding maturation is that it is 
impossible to know whether a term placenta became fully matured at the right time or 
too early. The term placentas can therefore not be evaluated regarding accelerated 
villous maturation. 
 
Placental infarctions can be seen grossly, but should be verified microscopically. 
Otherwise, there is also a risk for misclassifying. Becroft et al
33
 reported that almost a 
quarter of their macroscopical findings were misclassified. The most common 
misclassification was the macroscopical identification of a possible infarction that 
microscopically showed to be plaques of intervillous fibrin. The fact that we always 
diagnosed placental infarction microscopically is a major strength of this thesis. 
 
Formalin fixation is shown to increase the placental weight by approximately 10%.
195, 
196
 The Swedish placentas were weighed after formalin fixation and the Dutch before. 
As the Dutch material only belonged to one of the study groups, this could have 
resulted in a differential error, which could have led to the assumption that HELLP 
patients have placentas with lower weight, a conclusion not necessarily true. As the 
placentas were weighed differently in Sweden and Holland, we excluded the Dutch 
material regarding this parameter, thus decreasing the risk of bias. 
  
Fetal thrombosis can be postmortem in IUFD
13
 and as there is no technique to 
distinguish pre- and postmortem thrombosis, it is impossible to know if fetal 
thrombosis or death came first. 
 
Placental abruption is also a matter worth discussing. Not ideally, we have classified 
abruption differently in the studies included in this thesis. In the first two studies and in 
the last study, we included both clinically and pathologically diagnosed abruptions. In 
the third study we did not include the clinical ones, but neither did we analyze 
abruption in that study, as we focused on other variables.  
 
Oyelese et al
36
 argued that abruption is a clinical diagnosis and that a pathological 
examination regarding abruption should be avoided unless there was an adverse 
outcome of the pregnancy. This sounds reasonable, but we were interested in the 
impact of a histologically diagnosed abruption and its correlation with outcome. 
Therefore we never excluded the pathological diagnosis. Clinically and pathologically 
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diagnosed abruptions do differ as a clinical often is an acute, whereas a pathologically 
diagnosed abruption more often is chronic. In an ongoing parallel study
203
, it was 
shown that histologic abruption was correlated to hypoxic ischemic encephalopathy 
and adverse neonatal outcome, suggesting that the histopathological signs of abruption 
in the placenta may be important indicators, independent of the clinical picture. 
 
Inter-observer variability is generally high in placental pathology, especially if no 
agreement of diagnostic criteria has been settled.
204-206
 By letting one senior perinatal 
pathologist review all histopathological slides, we were striving to minimize this 
problem. In study II, the pathologists examined a portion of the placentas together, in 
order to establish common criteria and reach consensus on the histological diagnosis.   
 
6.1.3.2 Missclassification of PE diagnosis 
In the first studies, all diagnoses were verified in the clinical reports by collecting data 
on blood pressure levels, laboratory findings and symptoms. In the third study, we 
collected the cases from the hospital’s diagnostic database. A validation of the coding 
in the diagnostic database was done by reading medical records of >10% of the patients 
from each year. All of the patients were correctly diagnosed with PE. Among them, 
11.3% had mild PE, 88.7% severe PE and additionally, 24.2% HELLP syndrome. 
 
6.1.3.3 Confounding 
A confounder is an additional variable related to both the exposure and the outcome, 
therefore influencing the study on association between exposure and outcome. One way 
to minimize the effect of a confounder is to match participants in the different groups in 
regard to the confounder. However, it can be difficult to find pairs and the sample size 
can be reduced. Another possibility is to make a statistical analysis in which you 
include the confounder and therefore adjust for its effect.
200
  
 
In this thesis, the most obvious confounder is the gestational week. We chose to include 
the gestational week in the statistical analyses. Another confounder that we identified in 
the last study was presence of PE. Compared to the other studies, this sample consisted 
of an extremely premature population in which only some were complicated by PE. 
 
With a smaller study group, fewer variables can be included in the statistical analysis. 
This accounts for both outcome variables and confounders. The recommended number 
of variables is 1 per 10 cases.
198
 Depending on the sample sizes in our studies, we have 
either included only the gestational week in addition to one outcome variable, the 
gestational week in addition to several outcome variables or several possible 
confounders in addition to outcome variables. 
 
6.1.3.4 Selection bias 
Selection bias is present when exposure and outcome are related to the fact that a case 
is included in the study or not, or related to which study group the participant belongs 
to.
200
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In study I, 157 patients from Karolinska University Hospital Huddinge were included 
from the years 2000-2007. Approximately 1300 singleton PE cases were admitted at 
the hospital those years, so only about 12% of these women were enrolled in the study. 
Originally, only the years 2000-2004 were included, but as there were too few cases in 
the mild PE group we also included mild PE cases from 2005-2007. By doing this, the 
mild PE group grew from 29 to 41 cases. During the study period, there was no routine 
for referring mild PE cases, which most likely explain the difficulty to collect enough 
cases, although mild PE is more frequent than severe
4
. However, there is a high risk of 
a selection bias regarding the mild PE group. As there was no routine for referring 
them, the obstetrician possibly made the decision to refer the mild PE placenta as a 
consequence of a complicated delivery or an affected newborn. We cannot disregard 
the possibility that our finding with few differences between mild and severe PE might 
be biased by the selection of mild PE cases, maybe skewed towards a more severe 
group. 
 
In the second study, 117 out of approximately 1 000 PE cases (12%) during the study 
period at Karolinska University Hospital Huddinge were included. However, we only 
included severe PE cases and the 1 000 included both mild and severe, so the drop-out 
was probably less. Anyhow, the high frequency of drop-out may have given rise to a 
study sample which is not fully representative of the original population. 
 
In the third study, 544 placentas out of approximately 2800 (almost 20%) delivered at 
Karolinska University Hospital Huddinge and Solna, were examined. The small, 
although larger than in study I and II, proportion of placentas examined can have 
caused a selection bias. As the routines for referring mild PE differed during the years, 
a selection was again probably towards a severe PE population. First in late 2007, the 
routine for referring changed to include also mild PE placentas. Also during the years 
when both mild and severe PE routinely were sent for examination, a selection towards 
severe PE is likely as the proportion of mild PE cases was small also in those years. In 
addition, there might be a selection bias also within the mild PE group, as explained 
above in study II. However, this study correlated placental pathology, and not severity 
of the disease, with outcome. The proportion of examined placentas differed depending 
on year and hospital. In general, the referral rate grew from 9% to 27%. In the last 
study year, as many as 37% of the placentas from Karolinska University Hospital 
Huddinge were sent for examination. 
 
However, the number of examined placentas was even greater in the last study. Almost 
80% of all singleton infants born in gestational week 22-27 in Stockholm during the 
study period were included, which is a very high level and a strength of study IV.
207
 
 
6.2 FINDINGS AND INTERPRETATIONS 
An abnormal transformation of the spiral arteries, illustrated by decidual arteriopathy 
was associated with referral of the infant to neonatal care (study III). Although 
pathognomonic for PE, with the exception of fetal growth restriction without PE
19
, no 
other relationship could be found. Our interpretation is that the sampling error, when 
not examining placental bed biopsies, explains the lack of findings related to 
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arteriopathy. We believe that the true frequency of decidual arteriopathy is much larger 
in our material than what we found.  
  
Accelerated villous maturation was the most common finding in our PE materials. 
Although it cannot be adequately evaluated in the term placentas, it is likely that the 
villi of some term placentas also matured in advance. In study III, we found that 
placentas showing accelerated villous maturation were more likely to have a normal 
blood flow in the umbilical artery, showed a tendency to be inversely related to IVH 
≥grade 3 and more often resulted in a live born infant. Conversely, others have shown 
immature villi to be related to fetal death.
64, 208
 In study IV, the inverse relation 
between accelerated villous maturation and fetal death could not be confirmed, but this 
association has recently been found in another preterm population born before 32 
weeks’ of gestation.209  It could be that deaths in even earlier gestations, such as in our 
cohort born before 27 weeks’ of gestation, have causes not affected by villous 
maturation. In our cohort, fetal thrombosis was the strongest histopathological predictor 
of IUFD.  
 
In the last study (study IV), accelerated villous maturation was related to a better 
Apgar score and showed a tendency to be related to better language development at 2.5 
years of corrected age. In the absence of intervillous thrombosis it was also associated 
with a lower risk for neonatal mortality. In none of the studies, accelerated villous 
maturation was associated with adverse outcome of the infant or child. We speculate 
that accelerated maturation of the placental villi is a response to a hypoxic environment, 
and that it is a successful compensating mechanism leading to a better outcome of the 
infant. Maybe a child’s maturing ability is related to the maturing ability of the placenta 
as a consequence of a genetic predisposition, and in that case, the placenta mirrors the 
child’s future development.  
 
Smoking is, in contrast to all other cardiovascular risk factors, associated with a 
decreased risk of PE.
210
 Accelerated villous maturation can further be seen in placentas 
from mothers who smoke.
13
 Our finding with better outcome in the presence of 
accelerated villous maturation makes us wonder if the presence of accelerated villous 
maturation could have any role in the protective effect of smoking.  
 
Less surprising and mainly in accordance with previous studies
13, 19, 24, 140
, the better 
recognized hypoxic sign, infarction, was related to several adverse perinatal outcomes 
such as abnormal umbilical artery blood flow, lower umbilical artery BE, SGA-infants 
and IUFD (study III). In the last study (study IV), we could also find an association 
with CP, which is also in agreement with previous studies on macroscopically 
diagnosed infarctions.
27, 28
 Previous studies, that have shown associations between 
placental pathology and CP, have only diagnosed infarctions macroscopically. They 
most likely did not see the smallest infarctions and therefore mainly included the more 
extensive ones, influencing the infant to a greater extent.
27, 28
 Nonetheless, the risk of 
misclassification of infarction is high without a microscopic investigation
33
 and our 
study, which includes a microscopic verification of the macroscopic finding, confirms 
the relation between placental infarctions and a diagnosis of CP.   
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We could not find an association to development outcome, which could be explained 
both by the lower frequency of infarctions, as the last population was not a PE-
population, and by the fact that we could not estimate the amount of infarction in that 
study. The cohort came from all hospitals in Stockholm with differing practice in 
examining the placentas and an estimation of the amount of infarction was not always 
performed. Small infarctions are common and not associated with complications in an 
otherwise normal placenta.
19
 In contrast to the microscopic signs that were reexamined, 
the macroscopic features, such as amount of infarction, were gathered from the 
pathology reports. Furthermore, in a population born before gestational week 28, the 
cause of growth restriction is more likely of different origin than PE, thus not 
necessarily related to infarctions.
24
 In this population, we found instead a relation 
between SGA and fetal thrombosis, discussed below. 
 
A consequence of poor blood flow from the mother to the placenta and fetus could be 
growth restriction of both fetus and placenta. It is well known that the frequency of a 
low placental weight is more common in a PE-population.
13
 However, recently also 
heavier placentas have been reported in PE at term.
35
 Redman et al have suggested that 
the size of the placenta might matter as a larger placenta could release more debris, 
which could explain why multiple pregnancies are associated with an increased risk of 
PE.
73
  
 
In study III, we found that both a low and a high placental weight in relation to 
gestational week were related to major neonatal morbidity. DM is associated with large 
placentas
13
, but in our study, none of the women with a large placenta had DM. When 
we explored the major neonatal morbidities separately, we saw that a low placental 
weight was associated with NEC, whereas a high weight showed a trend to be related to 
morbidities such as cystic PVL and IVH ≥ grade 3.   
 
Interestingly, although the occurrence of accelerated villous maturation was high 
(73.1%) in our cohort, none of the preterm large placentas (n=12) showed any signs of 
accelerated maturation. We speculate that the placenta may compensate for the 
inadequate blood flow to the fetus in different ways, either by maturing the villi, or by 
growing faster. As mentioned earlier, acceleration of the villi seems to be a successful 
compensating mechanism. In contrast, a large placenta was related to major neonatal 
morbidity and specifically to severe morbidities of the brain. On the other hand, 
accelerated villous maturation showed a tendency to be associated with a lower 
incidence of IVH ≥ grade 3. So, from the maturing brain’s point of view, an 
acceleration of the villi would be preferred to a large placenta.  
 
The relation between abnormal placental weight and major neonatal morbidity was not 
confirmed in study IV. Perhaps the placental weight in the PE-population was more 
important than in the extremely premature population, in which chorioamnionitis was a 
more common finding.  
 
Fetal thrombosis, a vascular lesion on the fetal side of the placenta, is not associated 
with PE.
40
 While only 7.0% of the PE-placentas in study III had fetal thrombosis, it 
was found in 30.6% of the extremely premature placentas in study IV. In study IV, 
fetal thrombosis was related to SGA-infants, IUFD and also showed a tendency to be 
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associated with adverse cognitive function at 2.5 years of age. These results are in 
concordance with previous studies.
40, 42, 43
 In study III, fetal thrombosis was related to 
admission for neonatal care in the model analysis, but the CI of the OR included 1.00, 
probably as the frequency of fetal thrombosis in that material was too small. In the last 
study, where all were born before gestational week 27, all were obviously admitted to 
neonatal care unit.  
 
Our findings regarding chorioamnionitis differs between study III and IV, which can 
partly be explained by the different populations and the different patterns of pathology. 
Several studies have previously investigated the relations between chorioamnionitis and 
fetal outcome and development.
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Whereas accelerated villous maturation is a positive sign from the infant’s point of 
view, it might not benefit the mother. Both mild and severe PE showed significantly 
more accelerated villous maturation than the control group (study I). As severe PE is 
diagnosed in the presence of SGA, in an otherwise mild PE, we decided to present 
subgroups of the severe PE group in this thesis. As is seen when stratifying after SGA 
and AGA, descriptive data on accelerated villous maturation shows a higher frequency 
of accelerated maturation when the mother had high blood pressure or proteinuria or 
additional symptoms fulfilling the criteria for severe PE. 
 
We speculate, that the more hypoxia, the more common is accelerated villous 
maturation. The lack of normal placentation leads to an inadequate blood flow and 
unsatisfactory oxygen supply from the maternal side of the placenta to the fetal side. 
The hypoxic environment has shown to stimulate the placental villi, on the fetal side of 
the placenta, to secret sFlt-1
211
, a soluble vascular endothelial growth factor receptor, 
which spreads to the maternal circulation and could explain some of the maternal 
symptoms
74
. A previous study
212
 has shown that the level of sFlt-1 was significantly 
increased in the maternal blood of both mild and severe PE compared to controls, but 
there was only a trend towards a difference between mild and severe PE. However, a 
study by Taché et al
213
 showed that overexpression of sFlt-1 in the placenta strongly 
correlates both with the severity of hypertensive disease and accelerated villous 
maturation. 
 
Nonetheless, the frequency of ≥5% infarction significantly differed between mild and 
severe PE, as compared to the other pathological features (study I). Furthermore, all 
pathology that was more common in severe PE compared to the control group was also 
significantly more common in mild PE. This is not supporting the common notion that 
mild PE is not the same syndrome as severe PE, but only part of a normal physiological 
development in pregnancy. Also supporting the seriousness of a mild disease, 
Koopmans et al found that induction of labor beyond 37 weeks’ gestation improved 
maternal outcome also in mild PE.
141
  
 
Our results could indicate a similar underlying pathology in mild and severe PE, and 
that different individuals answer in diverse ways to this pathology. Let us assume that 
the progress of pathology is as follows: decidual arteriopathy – accelerated villous 
maturation – infarctions ≥5%, probably with acceleration and infarction developing in 
parallel. Perhaps the pathophysiological processes are the same until infarctions 
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develop, explaining why this variable showed differing frequencies. Could 
cardiovascular risk factors play a role here? The metabolic syndrome has previously 
been associated with PE
4, 214
 and it is possible that persons prone to develop 
cardiovascular disease might also be more likely to develop placental infarctions of 
≥5% and severe PE.  
 
No other studies have primarily examined extent and type of placental pathology in 
relation to severity of disease, but a study by Moldenhauer et al
68
 on placental 
pathology in relation to gestational age has shown more pathology in earlier gestational 
weeks. As our severe PE group is of a younger gestation than the mild group, we think 
that this supports our finding that infarctions are more common in the severe group. 
Still, Moldenhauer et al presented high frequencies of pathology in all gestational 
weeks, in comparison to the control group, also supporting our hypothesis that mild PE 
is part of the PE spectrum and not a normal physiological development. We do not 
doubt that there is an impact of gestation, but our interpretation is that both gestational 
week and the severity of disease is related to the extent and type of pathology. 
 
On the other hand, HELLP, which is a commonly accepted phenotype of PE, although 
with many differences in symptomatology, was shown to have a discordant 
histopathology (study II). In the PE group, we found more typical PE signs of 
abnormal uteroplacental blood flow, such as intervillous thrombosis, infarctions ≥5% 
and abruption. In patients with PE, the vascular resistance has been found to be 
reduced, whereas the vascular reactivity in HELLP patients did not differ compared to 
controls.
215
 This indicates that PE without HELLP might be a more vascular disease, 
which is also supported by our findings with more infarctions, thrombosis and 
abruption in the PE group.   
 
If PE is a vascular disease, leading to a chronic abnormal uteroplacental blood flow 
affecting growth of both fetus and placenta, the HELLP syndrome might be of a more 
toxic and acute nature. This could explain why pathology had not yet developed in the 
HELLP placentas and why fetal and placental growth was not affected to the same 
degree. This is supported by our finding of the shorter time between diagnosis and 
delivery in the HELLP patients. 
 
Previously, a study by Smulian et al
216
 on placental pathology in PE and HELLP 
patients showed a difference in placental abruption, in parallel with our results. 
However, they did not find any other pathological differences between the groups, 
which could be explained by their smaller study group. Another study
217
 did not find 
any difference in abruption either, but used less strict diagnostic criteria.  
 
However, in the comparison between PE and HELLP, it must be remembered that 
many of the HELLP patients also had hypertension and proteinuria of severe level and 
obviously have pathology related to that. Whether HELLP and PE are different diseases 
often affecting the same persons or rather part of the same disease is still unclear.  
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7 CONCLUSIONS 
 
It is debated whether mild PE is a physiological development of a normal pregnancy or 
part of the PE spectrum. Our results, with similar placental pathology in mild and 
severe PE in relation to controls, as well as the correlation between amount of 
pathology and the severity of PE (study I) point towards one disease originating from 
the placenta and giving rise to mild as well as severe PE, probably depending on the 
individual and the timing.  
 
The etiology of PE is still unknown, but the placenta is regarded as a central organ in 
the pathogenesis. As the placental pathology in severe PE with and without HELLP 
differed (study II), we conclude that the pathophysiological mechanisms in PE and 
HELLP might differ.  
 
Accelerated villous maturation was associated with normal blood flow in the umbilical 
artery in the PE population (study III), indicating a possible compensating mechanism 
for a hypoxic environment. On the other hand, an abnormal umbilical artery blood flow 
was related to low placental weight and infarctions ≥5%. 
 
Typical placental pathology in PE was further associated with perinatal and neonatal 
outcome of the infant (study III). Infarctions ≥5%, abnormal placental weight and 
decidual arteriopathy were related to different adverse outcomes, whereas accelerated 
villous maturation was inversely related to IUFD, once more suggesting a protective 
mechanism. 
 
In an extremely premature population, relations between placental pathology and 
perinatal and neonatal outcome could also be found (study IV), but the pattern was 
slightly different. Fetal thrombosis was related to IUFD and SGA. Furthermore, low 
placental weight was associated with IUFD. Also in this study, accelerated villous 
maturation was associated with a positive outcome: better Apgar score. 
     
As relations could be found between placental pathology and neonatal outcome both in 
the PE-population (study III) and the extremely premature population (study IV), we 
conclude that a careful pathological examination of the placenta without delay may add 
important prognostic information on the neonates at risk. 
 
We found a relation between placental infarction and CP, but no conclusions could be 
drawn regarding associations between placental pathology and development at 2.5 
years of age (study IV). However, we did see that accelerated villous maturation 
tended to be associated with better language development, fetal thrombosis tended to be 
related to adverse cognitive development and low placental weight tended to be related 
to worse motor development. Larger studies must be conducted in order to confirm 
those tendencies. 
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8 FUTURE PERSPECTIVES 
 
Severe PE obviously covers several different disease entities: women with HELLP 
syndrome, PE-patients with moderate hypertension and proteinuria but with the 
presence of fetal growth restriction and lastly, women with severe hypertension and 
proteinuria both with and without impact on the fetus. Further, non-PE pregnancies 
complicated by late spontaneous abortions and fetal growth restriction have been 
related to abnormal development of the spiral arteries, which is associated with PE. It 
will be intriguing to elucidate why some patients develop severe maternal symptoms 
and others no maternal symptoms, but growth restriction or even spontaneous abortion 
or IUFD. 
 
It would also be interesting to study the HELLP syndrome further. Many patients, but 
not all, do not fulfill the criteria for PE without their HELLP diagnosis. A 
characterization of HELLP patients without hypertension and proteinuria could add 
knowledge in the understanding of PE in relation to HELLP. 
 
Studying the developmental outcome should be done in a larger material and also at a 
longer term. If such studies confirm what we showed in this thesis, also studies on 
intervention, for example hypothermia, in patients with severe placental pathology, but 
otherwise not eligible for treatment, could be considered. 
 
All relations that we could find regarding accelerated villous maturation were positive 
findings. It would be interesting to investigate what makes some placentas “accelerate” 
their villi and others not. Also, can external factors, such as high altitude or smoking, 
stimulate the villi to accelerate and influence the infant positively?  
 
Maternal factors influencing the risk of PE could be studied further. Smoking is shown 
to protect against PE. The mechanisms behind that should be studied and could add 
knowledge both regarding pathophysiological mechanisms in PE and in the search for a 
treatment. Also, overweight and obesity are related to PE. Women are becoming more 
obese and it is essential to study this growing group further. 
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9 SAMMANFATTNING PÅ SVENSKA 
 
9.1 BAKGRUND 
Preeklampsi (PE) är vad man i folkmun kallar havandeskapsförgiftning, vilket drabbar 
2-7% av gravida kvinnor i världen. Både modern och barnet påverkas av sjukdomen 
och PE är en av de vanligaste orsakerna till att gravida kvinnor och deras barn blir sjuka 
och dör. I västvärlden är PE anledningen till 15-20% av mödradödligheten. 
 
När kvinnan blir gravid och moderkakan (placentan) bildas ska blodkärl som finns i 
livmodern omvandlas så att blodflödet till barnet blir optimalt. Omvandlingen av 
blodkärlen uteblir dock vid PE och istället får kärlen ett avvikande utseende, en sämre 
funktion och moderkakan drabbas av ett försämrat blodflöde.  
 
I moderkakan ser man oftare fynd som kallas för decidua arteriopati, infarkter, ablatio 
och intervillösa tromboser. Decidua arteriopati är det man ser när kärlen inte utvecklats 
på rätt sätt, såsom ovan beskrivits. Ytterligare väger ofta moderkakan mindre.  
 
Kvinnorna drabbas framför allt av olika grader av högt blodtryck samt läckage av 
äggvita i urinen. Om man inte åtgärdar sjukdomen kan den leda till ett kramptillstånd 
som kallas eklampsi. Exakt hur och varför PE uppstår är dock ännu inte helt klarlagt. 
Det enda sättet att bota sjukdomen är att förlösa barnet och moderkakan, vilket 
förklarar tillfrisknandet efter förlossningen. Sjukdomen kan dock uppstå redan i 
graviditetsvecka 20, då barnet ännu inte skulle klara sig utanför mammans mage. 
Sveriges omfattande mödrahälsovård syftar till stor del till att hitta kvinnorna som 
utvecklar PE. 
 
Sjukdomen kan ytterligare kompliceras av att mödrarna får något som kallas för 
HELLP syndrom, vilket kännetecknas av illamående, buksmärta och uppkastningar. 
Vid HELLP blir blodplättarna färre, blodkropparna går sönder och leverenzymerna 
stiger. Idag klassificeras HELLP som en sorts PE, trots att symtomen skiljer sig. Många 
patienter har såväl HELLP- som PE-symtom, men en del patienter har bara de ena 
symptomen.  
 
PE brukar delas in i en mild och en svår variant, beroende på graden av symptom. Vid 
högre blodtryck, än mer läckage av äggvita i urinen, tillägg av HELLP syndrom och 
tillväxtrubbning hos barnet klassas sjukdomen som svår. Det är debatterat huruvida en 
patient med mild PE har PE eller om mild PE bara är en naturlig utveckling av 
graviditeten. Ovan nämnda klassifikationsproblem kan vara en bidragande orsak till 
varför man inte lyckas komma fram till vad sjukdomen beror på. 
 
Barnen till kvinnor med PE växer ofta sämre och föds ofta för tidigt, vilket i sig är en 
riskfaktor för sjukdom och död. En låg födelsevikt har dessutom visat sig vara kopplad 
till hjärt- och kärlsjukdomar i vuxen ålder. Tidigare studier har beskrivit barnets hälsa 
hos PE-graviditeter, men få har letat efter samband mellan fynd i moderkakan och 
barnets sjukdomar och deras dödlighet. Det finns dock fynd i moderkakan som har 
visat sig ha samband med diverse sjukdomar hos barn.  
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9.2 FRÅGESTÄLLNINGAR 
1. Finns det någon korrelation mellan patologin i moderkakan och mammans 
svårighetsgrad av sjukdom? 
 
2. Är det någon skillnad i moderkakspatologi och frekvens tillväxt-hämmade barn 
hos svåra PE-fall med respektive utan HELLP syndrom? 
 
3. Förekommer något samband mellan moderkakans patologi vid PE och barnets 
sjuklighet och dödlighet under nyföddhetsperioden? 
 
4. Förekommer något samband mellan moderkakans patologi och barnets 
sjuklighet och dödlighet under nyföddhetsperioden hos mycket för tidigt födda 
barn? 
 
5. Har moderkakans patologi någon relation till barnets utveckling vid 2.5 års 
ålder hos mycket för tidigt födda barn?  
 
9.3 STUDIE I 
Materialet i denna studie består av 157 kvinnor med PE från Karolinska 
Universitetssjukhuset Huddinge. Av dessa hade 40 mild PE och 117 svår PE. 
Ytterligare rekryterades en kontrollgrupp med 157 kvinnor från graviditeter utan 
problem med högt blodtryck. Kontrollerna var matchade avseende graviditetsvecka.  
 
Kliniska data samlades från journaler. De nyfödda barnen diagnostiserade som SGA 
(små i relation till graviditetsvecka) när födelsevikten avvek mer än 2 standard 
deviationer enligt en skandinavisk respektive holländsk tillväxtkurva. En senior patolog 
eftergranskade samtliga mikroskopiska glas och var då blindad för klinisk data. 
Makroskopiska data hämtades från patologi-rapporten.  
 
Moderkakans vikt samt övriga patologiska variabler jämfördes mellan grupperna. 
Statistiska analyser gjordes med multipel regression, Chi-square-test samt T-test. I 
regressionsanalyserna justerades resultaten för graviditetsveckan när den visade sig ha 
en inverkan på utfallet.  
 
De patologiska fynden decidua arteriopati, accelererad villusmognad och andel 
infarkter i moderkakan ökade med svårighetsgrad av sjukdom hos mamman. Utöver att 
det var mer patologi vid svår PE, var patologin vid mild och svår PE liknande i 
jämförelse med kontrollgruppen.  
 
9.4 STUDIE II 
Denna retrospektiva studie inkluderar 178 kvinnor med svår PE från Karolinska 
Universitetssjukhuset Huddinge eller Free University Medical Center Amsterdam. Av 
dessa hade 96 svår PE utan HELLP och 82 fall hade svår PE med HELLP.  
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Kliniska data om patienterna och patologi-data hämtades från journaler och patologi-
rapporter. Födelsevikten klassificerades såsom i studie I.  
  
Barnets födelsevikt, moderkakans vikt samt övriga patologiska fynd jämfördes mellan 
de två grupperna. Statistiska analyser gjordes med logistisk regression, ANCOVA, Chi-
square test, Fisher’s exact test, Mann-Whitney-U-test och T-test beroende på vilken 
variabel som studerades. När graviditetsveckan visade sig ha en inverkan på utfallet 
inkluderades den i analysen som en kovariat. 
 
De patologiska fynden infarkter, intervillös trombos och ablatio var vanligare i PE-
gruppen utan HELLP. En högre moderkaks-vikt var vanligare i PE-gruppen med 
HELLP. PE-gruppen utan HELLP hade en högre frekvens av små barn i relation till 
graviditetsvecka.  
 
9.5 STUDIE III 
Denna studie inkluderar 544 kvinnor och barn där modern haft PE, eklampsi och/eller 
HELLP på Karolinska Universitetssjukhuset Huddinge eller Solna.  
 
Kliniska data hämtades från MFR (Medicinska födelseregistret), PNQ (Perinatala 
kvalitetsregistret) och journaler. Mikroskopiglasen eftergranskades av en patolog, som 
var blindad vad gällde utfall. Makroskopiska data hämtades från patologi-rapporterna.  
 
Utfallsvariabler som inkluderas var neonatal mortalitet, Apgar-poäng, behov av 
sjukhusvård, barn födda SGA (små för gestationsåldern), allvarliga 
nyföddhetssjukdomar, blodförgiftning och behov av respiratorvård. Allvarliga 
nyföddhetssjukdomar inkluderade cystisk PVL (periventrikulär leukomalaci), IVH 
(intraventrikulär blödning) ≥ grad 3, NEC (nekrotiserande enterokolit), ROP 
(nyföddhets-retinopati) ≥grad 3 och/eller svår BPD (bronkopulmonär dysplasi). 
 
Neonataldata korrelerades till typ av fynd i moderkakan. Multipla regressionanalyser 
användes, men även enklare statistiska metoder såsom Fisher’s exact test. I de multipla 
regressionanalyserna inkluderades graviditetsveckan när det var lämpligt. 
 
En avvikande moderkaks-vikt var relaterad till allvarlig nyföddhetssjukdom hos barnet. 
En låg vikt ökade risken såväl som en hög. Fyndet accelererad villusmognad var 
relaterad till minskad frekvens dödfödda barn. Fyndet decidua arteriopati var associerat 
med ökat behov av vård på sjukhus för barnet. Infarkter i ≥5% av moderkakan var 
relaterat till dödfödda barn och SGA-barn. Några typiska fynd i moderkakan i relation 
till dödlighet under nyföddhetsperioden hittades inte.  
 
9.6 STUDIE IV 
Materialet i denna studie består av 167 barn och mödrar med förlossning före 
graviditetsvecka 27 i Stockholm län. Av dessa var 62 dödfödda och 38 dog inom en 
månad. Vid 2.5 års ålder undersöktes 59 med avseende på utveckling.  
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Kliniska data hämtades från PNQ och från journaler. Alla mikroskopiglas av 
moderkakorna eftergranskades av en patolog som var blindad för utfallet. 
Makroskopiska data hämtades från patologi-rapporten.  
 
Utfallsvariabler som studerades var SGA-barn, allvarliga nyföddhetssjukdomar, 
blodförgiftning samt behov av behandling av kvarstående duktus arteriosus. Allvarliga 
nyföddhetssjukdomar definierades såsom i studie III. Data om allvarlig neuromotorisk 
(CP) eller neurosensoriskt (allvarlig synnedsättning och dövhet) handikapp 
analyserades. Allvarlig synnedsättning definierades som blindhet eller förmåga att 
endast se ljuset från en lampa. Allvarlig hörselnedsättning definierades som en 
oförmåga att höra trots hörapparat. Kognitiv, språklig och motorisk utveckling vid 2.5 
års ålder bedömdes med hjälp av Bayley-III utvecklings-tester och jämfördes med 
normala resultat hos skandinaviska barn.  
 
Neonataldata samt neurologiska data och utfall vid 2.5 års ålder korrelerades till fynd i 
moderkakan. De olika statistiska metoderna som användes var logistisk regression, som 
inkluderade olika confounders som visade en inverkan på utfallet, stegvisa statistiska 
metoder, liksom ANCOVA-analyser (analys med kovariater) samt enklare analyser 
som Fishers exact test, Mann-Whitney U-test och T-test.  
 
Accelererad villusmognad var associerad med bättre Apgar-poäng. Fetala tromboser 
och en låg moderkaks-vikt var relaterade till både dödfödda barn och SGA-barn. 
Infarkter i placentan var associerade med en CP diagnos hos barnet. Accelererad 
mognad visade en tendens att vara relaterat till bättre språklig utveckling, fetala 
tromboser till lägre kognitiv funktion och en låg vikt till sämre motorisk utveckling. 
 
9.7 SLUTSATSER 
 Att patologin vid mild och svår PE liknade varandra samt skiljde sig från 
kontrollerna indikerar att de underliggande mekanismerna kan vara desamma 
vid mild och svår PE. Detta talar emot att mild PE är en naturlig utveckling av 
graviditeten.  
 
 Att patologin i moderkakorna från PE med respektive utan HELLP skiljde sig 
skulle kunna tyda på att PE och HELLP är olika sjukdomar med olika etiologi, 
men som ofta drabbar samma patienter.   
 
 Hos såväl barn födda av PE-kvinnor som extremt för tidigt födda barn finns det 
fynd i moderkakan som korrelerar med det neonatala utfallet. Hos dessa barn 
skulle undersökning av moderkakan kunna förbättra riskbedömningen av det 
nyfödda barnet. 
 
 Infarkter i placentan verkar öka risken för att barnet drabbas av CP. För att 
några slutsatser ska kunna dras avseende associationer mellan fynd i 
moderkakan och barnets utveckling vid 2.5 års ålder behövs större studier. De 
tendenser som framkom tyder på att flera samband mycket väl skulle kunna 
finnas. 
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